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Abstract  
 
Immunoglobulin light chain amyloidosis (AL) is the most common form of 
systemic amyloidosis in which a plasma-cell dyscrasia results in the 
overproduction of amyloidogenic immunoglobulin light chains (LC). Although 
LC organize in extracellular deposits in different target organs, approximately 
75% of patients manifest heart involvement at presentation, with a median 
survival of only 6 months if chemotherapy fails to stop LC production. Although 
an active role of radical oxygen species (ROS) has already been envisaged, the 
actual mechanisms behind their generation remain elusive.  
In this study, it was observed that amyloidogenic LC purified from patients with 
cardiac involvement intrinsically generated high levels of ROS and, when 
administered to C. elegans resulted in ROS production. These species can directly 
target the pharyngeal cells, causing remarkable damage particularly at the 
mitochondrial level, similar to that observed in amyloid-affected hearts from AL 
patients. Tetracycline counteracted all these ROS-mediated effects and, when 
added to standard chemotherapy, they reduced early deaths in patients with 
cardiac AL. To limit and repair the stress-induced damage, different intracellular 
signalling events are activated. In particular, the nuclear translocation of the 
FOXO/DAF-16 transcription factor triggers the transcription of stress-responsive 
genes, including heat-shock protein (hsp)-16.2 and manganese superoxide 
dismutase (sod)-3, and controlling stress resistance and survival. 
All these effects were entirely dependent on the presence of metal ions, 
particularly copper. Metal chelators or metal-binding compounds, particularly the 
new drug PBT2, block ROS production and interrupt the vicious cycle of 
oxidative stress. In C. elegans, low doses of PBT2 in combination with 
tetracycline result in a synergistic beneficial effect, highlighting the potential 
application of this pharmacological strategy for AL patients. These findings 
indicate that metal-induced oxidative stress, already reported to be linked with 
some neurological disorders, is also a key element in cardiac AL amyloidosis. 
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The central role of proteins in ensuring many biological functions is specifically 
related to their amino acid sequence and consequently their three-dimensional 
structure. The correct folding of proteins is finely regulated by different molecular 
mechanisms which assist them to adopt and maintain their native functional 
conformational state and inhibit the formation of alternative nonfunctional 
assemblies (Soto, 2003). In the last decades, an increasing number of human 
diseases have been identified as associated with changes in protein structure. 
These pathological conditions referred to as “protein misfolding diseases”, 
involve the production of proteins that do not achieve their functional 
conformational state or adopt an alternative one. These disorders can be ascribed 
to: i) the degradation of a specific precursor protein unable to fold correctly (loss 
of function disorders, i.e. cystic fibrosis) or ii) the overproduction and aggregation 
of misfolded proteins in different organs (gain of toxic function disorders) 
(Blancas-Mejia and Ramirez-Alvarado, 2013). Amyloidoses represent an example 
of this last category of protein-misfolding diseases. 
1.1 Amyloidoses 
Amyloidoses are a heterogeneous group of protein misfolding diseases whose 
hallmark is the anomalous extracellular or intracellular deposition of pathogenic 
proteins in different tissues and/or organs (Chiti and Dobson, 2006, Blancas-Mejia 
and Ramirez-Alvarado, 2013). The term amyloid, derived from the Latin 
amiloideus ("starch-like"), was used for the first time in medicine in 1854 by 
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Rudolf Virchow to indicate small round proteinaceous deposits localized in the 
nervous system, sharing structural properties similar to starch (Naito, 2014). 
The classification of amyloidoses is based on the biochemical nature of the 
precursor protein involved in the pathology (Perfetti et al., 2001). To date, 37 
different proteins with amyloid-like features have been identified, each one 
associated to a specific hereditary or sporadic pathological disorder (Chiti and 
Dobson, 2017). Although all these proteins are unrelated and do not share 
similarities in their amino acid sequence (Falk et al., 1997, Chiti and Dobson, 
2006), all of them produce insoluble extracellular or intracellular deposits with a 
common β-fibrillar structure. It was observed that these aggregates share common 
biochemical and tinctorial properties (Soto, 2003), including the resistance to 
denaturants and proteases’ degradation and the ability to show apple-green 
birefringence when they are analyzed by polarized light microscopy after Congo 
red staining (Howie et al., 2008, Soto, 2003).  
The mechanism driving protein aggregation was first described for the amyloid-β 
(Aβ) peptide, actively involved in Alzheimer’s disease (AD), which was then 
investigated and defined as “amyloid cascade”: a multistep process common to all 
the proteins involved in amyloid diseases (Verma et al., 2015). During the early 
stages of the aggregation pathway, monomers of a protein can start to self- 
aggregate leading to the formation of small reactive intermediates known as 
oligomers (Figure 1).  
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Figure 1| A schematic representation of protein misfolding and aggregation 
During misfolding and aggregation, the polypeptide chain undergoes different large 
conformational rearrangements leading to the formation of unstable misfolded 
intermediates. These species, through intermolecular interactions with other molecules, 
assemble to small oligomers which, with further growth, produce amyloid-like fibrils. The 
molecular mechanisms driving protein oligomerisation and aggregation are not yet clear. 
Adapted from (Knowles et al., 2014).  
 
These soluble species can cluster to form beaded chains called protofibrils 
(Knowles et al., 2014, Chiti and Dobson, 2017). The rearrangement of these 
assemblies is then involved in the formation of mature fibrils that are highly 
ordered β-sheet structures prone to aggregate and form amyloidogenic deposits 
(Knowles et al., 2014, Siddiqi et al., 2017).  
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Whether oligomers or amyloid fibrils are responsible for the onset and 
progression of amyloidoses, remain a matter of debate (Nuvolone and Merlini, 
2017a). For a long time, researchers believed that fibrillar deposits were the most 
toxic species in amyloidoses. To date, it is known that, although the accumulation 
of these species in the extracellular or intracellular compartments alters the tissue 
architecture, there is not a correlation between the total amount of aggregates and 
the functional alterations observed (Perfetti et al., 2001). Recently, it was 
hypothesized that oligomers of different amyloidogenic proteins, due to the 
exposure of hydrophobic domains, induce toxicity through a common mechanism 
(Gandy et al., 2010, Sengupta et al., 2016, Chiti and Dobson, 2017, Knowles et 
al., 2014). For these reasons, they are considered the most relevant species able to 
induce biological effects such as reactive oxygen species (ROS) production, cell 
death and tissue damage (Gandy et al., 2010, Sengupta et al., 2016, Chiti and 
Dobson, 2017, Knowles et al., 2014). The elucidation of the molecular 
mechanisms determining these pathologies is crucial to clarify and develop new 
therapeutic approaches to treat and prevent them.  
To this end, considerable efforts have been made in the last decade to develop 
new therapeutic strategies aimed at counteracting Aβ toxicity in AD. Passive 
immunization, based on the administration of exogenous monoclonal antibodies, 
is an emerging approach for the treatment of AD (van Dyck, 2018). Different 
antibodies against Aβ amyloid have been proposed (Schilling et al., 2018) and 
among them, the human monoclonal antibody aducanumab is particularly 
promising (Sevigny et al., 2016, Arndt et al., 2018). In a phase 1b study, it was 
demonstrated that aducanumab targets explicitly Aβ aggregates, including soluble 
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oligomers and insoluble fibrils, but not monomers (Sevigny et al., 2016, van 
Dyck, 2018, Arndt et al., 2018). Furthermore, the administration of higher doses 
of aducanumab once a month for up to 54 weeks reduces the amount of the 
amyloid burden in the brain of AD patients, also ameliorating their cognitive 
ability (Sevigny et al., 2016, van Dyck, 2018). To date, the effects of low doses of 
aducanumab are under evaluation in phase 3 clinical trial for early AD (van Dyck, 
2018).  
Overall, these data contributed to elucidate the molecular mechanisms involved in 
the AD and to develop new therapeutic strategies aimed at reducing Aβ toxicity. 
Moreover, due to the specificity of aducanumab for Aβ aggregates, new 
antibodies specifically targeting oligomers could also be designed for other 
protein misfolding diseases.  
1.2 Systemic amyloidoses 
Based on the specific localization of the fibrillary aggregates, amyloidoses can be 
distinguished in localized or systemic amyloidoses. The presence of deposits in 
the site of precursor production is known as localized amyloidosis while their 
localization at one or more sites distant from the site of precursor synthesis is 
referred to as systemic amyloidosis (Nienhuis et al., 2016). In both cases, the 
production and accumulation of a large amount of these proteins in a specific 
tissue cause characteristic clinical symptoms (Chiti and Dobson, 2017).  
Systemic amyloidoses are a group of rare, heterogeneous diseases which 
prognosis depends upon a specific precursor protein and the affected organs 
(Nuvolone and Merlini, 2017b). In these pathologies, a large quantity of a 
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misfolded precursor protein is synthetized and then, through the bloodstream, it is 
deposited in extracellular compartments of different organs as insoluble fibrillar 
assemblies. The accumulation and deposition of the amyloidogenic proteins lead 
to cellular death and organ dysfunction (Nuvolone and Merlini, 2017b).  
To date, 15 systemic amyloidoses have been identified (Table 1), each one 
associated to a specific precursor protein.  
1.3 Immunoglobulin light chains amyloidosis 
Immunoglobulin light chains (LC) amyloidosis (AL amyloidosis) is the most 
common form of systemic amyloidosis in Western countries, with an incidence of 
10 new patients per million per year (Blancas-Mejia and Ramirez-Alvarado, 2013, 
Nuvolone and Merlini, 2017b). A plasma cell dyscrasia causes it, that is the  
abnormal   proliferation of a plasma cell clone in the bone marrow (Patel and 
Hawkins, 2015).  
Under physiological conditions, immunoglobulins are produced and assembled in 
the bone marrow by plasma cells to form a Y-shaped tetramer consisting of two 
identical LC (kappa or lambda isotype) covalently linked to two identical heavy 
chains. LC are physiologically synthesized slightly in excess than heavy chains: 
most of them are then assembled into intact immunoglobulins while those that do 
not bind to heavy chains are secreted in the bloodstream as monomers or dimers 
free LC (Selvaratnam et al., 2016). Due to their small size, most of free LC are 
filtered by the kidney across the glomerulus, reabsorbed in the proximal tubules 
and catabolized by proteases (Solling, 1981, Strober and Waldmann, 1974). For 
this reason, in healthy patients the total amount of LC detected in the urine, 
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known as Bence-Jones protein (BJ), is low (1–10 mg/24 h) (Selvaratnam et al., 
2016, Strober and Waldmann, 1974). 
Table 1| Systemic amyloidoses 
 
Adapted from Nuvolone et al., 2017 (Nuvolone and Merlini, 2017b) and Chiti and 
Dobson, 2017 (Chiti and Dobson, 2017).  
 
In AL amyloidosis a neoplastic plasma cell clone no longer assembles complete 
immunoglobulins but overproduces amyloidogenic LC, with lambda isotype 
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predominance (Perfetti et al., 2001). Through the bloodstream, LC are delivered 
to the kidney causing an increase of the glomerular filtration. However, the 
resorption capacity of proximal tubules is not sufficient to completely remove the 
LC burden, leading to the detection of higher concentrations of LC in the urine. At 
the same time, the increased misfolded LC released into circulation shifts the 
equilibrium towards ﬁbril formation leading to amyloid deposition in the 
extracellular space. The persistence of the amyloidogenic aggregates in the tissues 
disrupts their architecture causing organ failure (Merlini, 2012, Falk et al., 2016, 
Merlini and Stone, 2006, Kastritis and Dimopoulos, 2016).  
AL amyloidosis is closely related to multiple myeloma, a β-cell dyscrasia in 
which a neoplastic plasma cell clone produces an excess of non-amyloidogenic 
LC in the bone marrow that infiltrates the bone (Falk et al., 2016). For this reason, 
myeloma’s symptoms include bone lesions, anaemia, hypercalcemia and renal 
insufficiency, but no amyloid deposits have been ever revealed (Merlini et al., 
2011, Ramirez-Alvarado et al., 2007). Contrary, in AL patients a small neoplastic 
clone typically resides in the bone marrow and secretes LC into the circulation. 
Therefore, in AL amyloidosis the clinical symptoms are not due to the 
proliferation of the plasma cell clone in the bone marrow but to the buildup of 
circulating amyloidogenic LC produced by the neoplastic clone which is the 
responsible for organ dysfunction (Falk et al., 2016, Merlini et al., 2011, 
Nuvolone and Merlini, 2017a).  
No clear biophysical and biochemical differences have been till now observed 
among LC from AL- and myeloma-affected patients. The only discriminating 
characteristic remains the peculiar ability of LC causing AL to form amyloid 
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assemblies whereas are not formed at all by myeloma LC. For all these reasons, 
non-amyloidogenic LC purified from myeloma- patients represent the best control 
for studies involving LC from AL amyloidosis.  
 
Clinical features of AL amyloidosis  
The prognosis of AL amyloidosis is related to the organ involved in LC 
deposition, most frequently heart (74%), kidney (65%), liver (17%), 
gastrointestinal tract (8%), soft tissues (17%) and peripheral (14%) or autonomous 
nervous system (15%) (Figure 2) (Merlini, 2012, Blancas-Mejia and Ramirez-
Alvarado, 2013). However, the molecular mechanism driving the organ tropism it 
is not yet clear (Westermark, 2012). 
AL patients with cardiac involvement show the worst prognosis as compared to 
other organ involvement, with a median survival of less than a year after 
diagnosis. Virtually, all AL-affected patients rapidly develop heart failure and 
ventricular arrhythmias and die from cardiac damage, independently from the 
localization of amyloid deposits (Merlini, 2012). For this reason, the elucidation 
of the molecular mechanisms and the development of a new appropriate 
therapeutic strategy are crucial to limit the LC cardiotoxicity and improve 
patients’ survival. 
Great efforts have been made to characterize the amyloidogenic clone involved in 
AL amyloidosis and to define the mechanisms underlying the LC propensity to 
aggregate and deposit in specific organs, but with limited success (Sirac et al., 
2018). Although it was reported that certain LC germline genes could be 
associated with specific organ targeting (i.e. IGLV1-44 has been associated with 
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heart involvement) (Perfetti et al., 2012), the molecular mechanisms involved in 
LC cardiotoxicity are still under investigation and it is not possible to predict the 
protein’s ability to target specifically the cardiac tissue (Diomede et al., 2014a). 
 
Figure 2| Schematic representation of tissues involved in AL amyloidosis 
In AL amyloidosis, a plasma cell clone secretes a large amount of misfolded LC. The 
wrong folding of this protein is caused by mutations (symbolized by the red dot) in the 
critical structural sites of LC. These amyloidogenic proteins are prone to aggregate and 
deposit in different tissues and organs leading to failure organs, mainly in the heart. 
Adapted from (Merlini, 2012). 
 
Early diagnosis in AL-affected patients is crucial to stop the progressive organ 
dysfunction, above all cardiac dysfunction that is mainly involved in patients’ 
survival (Palladini and Merlini, 2009). Nevertheless, although cardiac damage is 
related to the myocardial fibril deposition, the presence of aggregates alone does 
not correlate with the severity of the pathology (Liao et al., 2001).  
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At present, the standard therapy for AL amyloidosis derives from the 
chemotherapy regimens initially developed for the treatment of multiple 
myeloma. It is based on the use of a combination of alkylating agents (melphalan, 
cyclophosphamide), steroids, proteasome inhibitors (bortezomib, ixazomib, 
carfilzomib), immunomodulatory drugs (thalidomide, lenalidomide, 
pomalidomide) and monoclonal antibodies (daratumumab, elotuzumab) 
(Nuvolone and Merlini, 2017a, Kastritis and Dimopoulos, 2016), eventually 
associated with autologous stem cell transplantation (Hrncic et al., 2000). This 
approach is aimed to destroy the neoplastic plasma cell clone the new synthesis of 
LC rapidly, blocking the end-organ damage and leading thus to prolonged 
patients’ survival (Falk et al., 2016).  
Although this treatment improved the outcomes of most of AL patients, the 
prognosis of more than 20% of patients with severe cardiac injury is still poor 
(Kastritis and Dimopoulos, 2016). They are extremely fragile due to the severe 
cardiac involvement, and they do not tolerate high-dose of chemotherapeutics 
(Merlini, 2012). The results are that, although they need urgently of effective 
therapy, most of them die before starting or during the therapy (Merlini, 2012). 
For this reason, the elucidation of the mechanisms driving the pathology and 
consequently develop adequate therapeutics approaches are urgently needed. 
Clinical findings evidenced that the suppression of the circulating oligomeric LC 
following chemotherapy is associated with a significant improvement of cardiac 
function, as demonstrated by the decrease of different cardiac biomarkers, 
including the N-terminal natriuretic peptide type B (NT-proBNP) and cardiac 
troponins (cTn) (Nuvolone et al., 2015, Sanchorawala, 2006), resulting in the 
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extension of the patients’ survival. Surprisingly, echocardiography analysis 
revealed that the amelioration of the clinical signs was not accompanied by a 
reduction of the amyloid deposits localized in the myocardium, indicating that the 
standard chemotherapy currently employed prevents the deposition of new LC’s 
aggregates, without removing those already existing (Merlini et al., 2011).  
The clinical presentations of AL patients are highly heterogeneous. Moreover, 
different biological, biochemical, and biophysical factors play a key role in 
determining the disease (Diomede et al., 2014a). To this end, the generation of 
appropriate, controllable model animals recapitulating the in vivo mechanisms of 
the pathology is crucial to design and evaluate innovative therapeutic approaches 
(Diomede et al., 2014b, Sirac et al., 2018, Diomede et al., 2014a). 
 
Models of LC-induced cardiotoxicity  
Although different groups have made great efforts, no reliable animal models are 
available to investigate AL amyloidosis (Sirac et al., 2011). This means that the 
pathogenic role of soluble LC and the mechanisms leading to organ damage are 
difficult to investigate. In vitro and ex vivo models have been employed to clarify 
these processes (Diomede et al., 2014b, Nuvolone and Merlini, 2017a).  
In 2004, Brenner et al. investigated the cytotoxicity of LC purified from the urine 
of AL patients on cardiomyocyte (Brenner et al., 2004). They demonstrated that 
only soluble cardiotoxic LC, but not control LC purified from multiple myeloma-
affected patients, induce oxidative stress by increasing the production of reactive 
oxygen species (ROS). These reactive species are involved in the impairment of 
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cell contractility and relaxation through alterations of intracellular calcium 
homeostasis (Brenner et al., 2004).  In 2001, Liao et al. demonstrated that the 
infusion of BJ LC purified from patients with cardiac involvement causes a rapid 
and permanent ventricular dysfunction in isolated mouse hearts, independently 
from fibrils formation (Dispenzieri and Merlini, 2016, Milani et al., 2018, Liao et 
al., 2001).  
Overall, these experimental findings indicate that circulating LC, but not fibrillar 
deposits, are directly involved in cardiac dysfunction in AL amyloidosis, 
determining the severity of heart failure and patients survival (Merlini et al., 
2011). 
The development of suitable animal model steadily overproducing LC and 
forming amyloid deposits is crucial to elucidate the molecular mechanisms 
involved in the onset and progression of cardiotoxicity in AL amyloidosis.  
 
 
1.4  Caenorhabditis elegans  
C. elegans is a small, free-living soil nematode, commonly referred to as 
roundworms. It was used for the first time as a model organism by Sydney 
Brenner in the mid-1960s, to investigate the mechanisms involved in 
developmental biology and neurobiology (R. and L., 2008). Since that moment, 
various groups around the world used the nematode C. elegans as simplified in 
vivo animal model for different human pathologies (Table 2), providing 
considerable insights into the mechanisms of biology including programmed cell 
death, cell signalling, genomics, metabolism and ageing. 
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Adult animals are 1-mm long and have a diameter of 80 μm, they are transparent 
and contain 959 somatic cells, whose 302 are neurons, and its cell lineage is 
invariant among individuals (Chisholm A. D., 2006). Moreover, C. elegans has a 
short life cycle of about 3 days at 20°C and a lifespan of about 2-3 weeks under 
suitable living conditions. In the wild, C. elegans feeds on available microbes, 
primarily bacteria and in the laboratory, it is cultivated in large numbers in a 
liquid medium or on agar plates, seeded with Escherichia coli (E. coli) as a food 
source (Markaki and Tavernarakis, 2010). Its culture requirements are relatively 
simple and can be preserved cryogenically (Consortium, 1998). 
C. elegans was the first animal whose genome has been completely sequenced, in 
1998 (Consortium, 1998). Although it is a simple organism, it shares similar 
molecular pathways with mammals. Also, more than 60% of human disease-
related genes are homologous in worms (R. and L., 2008, Shen et al., 2018).   
 
Biology of C. elegans 
C. elegans has two sexes, hermaphrodite and male. Both sexes have five pairs of 
autosomes and one pair of sex chromosomes. However, while hermaphrodites 
have two X chromosomes (XX), males are generated by spontaneous non-
disjunction in the hermaphrodite germ line, leading to a single X chromosome 
(XO) (Herman, 2005).  
They can be distinguished for the overall body size (male is smaller than the 
hermaphrodite) and for the morphology of the tail (the hermaphrodite adult tail tip 
is long and pointed, while the male tail tip is blunt ended) (Figure 3 and Figure 4). 
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Figure 3| Anatomy of the adult C. elegans hermaphrodite  
Adapted from (Palikaras and Tavernarakis, 2013). 
 
 
The dominant sexual form is the hermaphrodite that, producing both oocytes and 
sperm, reproduces by self-fertilization (Zarkower, 2006). During its lifetime, a 
single hermaphrodite generates a large number of worms (about 300 organisms) 
all genetically identical to each other (Palikaras and Tavernarakis, 2013).  
Males produce only sperm, and under physiological conditions, they arise with a 
low frequency, usually 0.1%. In adverse conditions, including limited food or 
high temperature, their number spontaneously rises to increase the chances to 
survive to the adverse environmental conditions (Palikaras and Tavernarakis, 
2013). 
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Figure 4| Anatomy of the adult male 
Adapted from (Palikaras and Tavernarakis, 2013). 
 
Under optimal conditions, the life cycle of C. elegans occurs in about 3 days at 
22°C. It consists of different stages leading to the development of an adult worm, 
which then lives for about 2 – 3 weeks (Figure 5). After fertilization of an oocyte, 
through many cell divisions, embryos are formed within the mother's uterus 
(Altun, 2009). When the embryo reaches the gastrula stage (approximately 30-
cell), the worm egg is laid, and the embryonal development proceeds outside the 
worm. Through additional cell divisions, the cell number of embryo increases 
leading to the formation of organs. The hatching of the egg occurs when the 
pharynx starts to pump. 
After hatching, C. elegans post-embryonic development proceeds through four 
larval stages ( L1–L4) before it reaching adulthood (Figure 5) (Altun, 2009).   
Alternatively, under unfavourable conditions for further growth, including limited 
food or high temperature, L2 larvae can achieve an alternative larval stage called 
"dauer” in which feeding is arrested, and locomotion is reduced In this stage, they 
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can survive for 3–6 months (4–8 times the average lifespan) (Altun, 2009). If the 
growth conditions improve again, the dauer larvae can resume their normal 
developmental cycle to reach the sexual maturity (Altun, 2009).  
 
Figure 5| Life cycle of C. elegans  
Adapted from (Altun, 2009). 
 
C. elegans as a model for investigating AL amyloidosis 
In the last years, due to the complexity and the limitation of mammalian 
organisms (e.g. costs, long lifespan), invertebrate models such as C. elegans has 
been used as a rapid and versatile animal model to recapitulate the molecular 
events occurring in different pathologies, including amyloidosis (Table 2) 
(Diomede et al., 2014b).  
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Table 2| C. elegans as animal model to investigate different pathologies  
 
Adapted from (Markaki and Tavernarakis, 2010). 
 
Moreover, C. elegans has also been employed as innovative in vivo animal model 
for rapid evaluation of the potential toxicity of different protein assemblies 
(Diomede et al., 2014b, Stravalaci et al., 2012). In particular, it was demonstrated 
that the administration of soluble oligomers of Aβ, but not monomers or larger 
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assemblies, act as “chemical stressors” inhibiting the C. elegans’ pharyngeal 
pumping rate (Diomede et al., 2014b, Stravalaci et al., 2012). 
These findings are based on the knowledge that sublethal doses of different 
compounds, including alcohol and heavy metals, are detected as “chemical 
stressors” by the pharynx of the worm, an organ crucial for the worm’s feeding 
and survival (Jones and Candido, 1999). In 1999, Jones & Candido demonstrated 
that these molecules, through the production of cellular stress proteins, inhibit the 
contraction and relaxation of the nematodes’ pharynx rapidly to limit the intake of 
the toxic compounds (Jones and Candido, 1999).  
C. elegans’ pharynx is considered ortholog to the vertebrate heart. Evolutionary 
conserved cardiac transcription factors finely regulate the development of both 
organs, and they both possess an automatic contractile activity regulated by 
similar electrical circuitry and show similar types of ion channels (Avery and 
Shtonda, 2003, Diomede et al., 2014b, Mango, 2007, Diomede et al., 2014a). 
Based on this knowledge, we hypothesized that LC directly involved in cardiac 
injury in AL patients could affect C. elegans’ pharyngeal motility (Diomede et al., 
2014a, Diomede et al., 2014b). To this end, we used for the first time the 
nematode C .elegans as an animal model to investigate in vivo the organ tropism 
of LC in AL amyloidosis (Diomede et al., 2014a, Diomede et al., 2014b). In this 
study, we demonstrated that cardiotoxic LC, but not myeloma proteins, are 
detected as chemical stressors from C. elegans, which reacts by limiting feeding 
(Diomede et al., 2014a). 
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In particular, soluble amyloidogenic LC with different organ tropisms purified 
from AL patients and non-amyloidogenic LC from multiple myeloma patients as 
control LC have been used (Diomede et al., 2014a, Diomede et al., 2014b).   
After administration to worms, the scoring of the pharyngeal pumping rate has 
been then used as a powerful tool to determine the potential LC cardiotoxicity 
(Diomede et al., 2014a, Diomede et al., 2014b). 
The pharyngeal impairment caused by cardiotoxic LC, but not non-cardiotoxic 
LC, is dose-dependent and it became maximal at 100 µg/ml, which is the 
concentration of circulating levels of free LC measured in the blood of patients 
with AL amyloidosis [30]. Furthermore, this effect persisted up to 48 hours after 
administration, indicating that cardiotoxic LC induce a permanent dysfunction 
(Diomede et al., 2014a). 
Cardiotoxic LC obtained from different AL patients specifically impaired the 
pharyngeal pumping rate of nematodes, independently if they have been purified 
from urine or serum of AL patients or obtained as recombinant proteins (Diomede 
et al., 2014a). No toxic effects were observed when nematodes were fed with LC 
from AL- affected patients involving organs other than the heart (e.g. kidney and 
soft tissue) or with myeloma ones (Diomede et al., 2014a). 
Contrary to what observed with the Aβ protein, no differences in oligomerization, 
secondary structure, stability, and surface hydrophobicity have been observed 
between cardiotoxic and non cardiotoxic LC. These data indicate that the 
pharyngeal dysfunction caused by cardiotoxic LC is not due to peculiar protein 
folding or propensity to form aggregates, compared with the non-toxic LC 
proteins (Diomede et al., 2014a). 
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Interestingly, the irreversible impairment of pumping function caused by 
cardiotoxic LC is related explicitly to mitochondrial ROS production in the 
worms’ pharynx. The administration of cardiotoxic LC, but not myeloma, 
significantly increased the fluorescence detected by MitoSOX, a mitochondria-
specific redox-sensitive dye, indicative of an enhanced oxidant burden. Moreover, 
similar results were obtained after exposition nematodes to 0.1 mM H2O2, used as 
positive control of the experiment. No specific MitoSOX fluorescence has been 
observed in the pharynx of worms fed myeloma protein or vehicle.   
Due to its ability to continuously contract and relax, the pharynx of C. elegans is a 
mitochondrial-rich tissue. Mitochondria continuously supply energy for 
contraction and play a crucial role in ensuring the physiological function of this 
organ (Diomede et al., 2014a, Diomede et al., 2014b). However, they are also 
highly sensitive to oxidative damage. This means that ROS production induced by 
cardiotoxic LC in the pharynx cause a significant reduction of Adenosine 
triphosphate (ATP) available for the contraction, leading to loss of organ function 
(Diomede et al., 2014a, Diomede et al., 2014b).  
Moreover, it was demonstrated that cardiotoxic LC, but not myeloma proteins, 
through ROS generation lead to cell death and reduction in the C. elegans’ 
lifespan (Diomede et al., 2014a). 
This innovative nematode-based approach is also eligible for the inexpensive 
screening of candidate drugs counteracting LC toxicity. It was demonstrated that 
the pharyngeal impairment caused by cardiotoxic LC was counteracted by anti-
oxidant molecules able to reduce the mitochondrial ROS burden and restoring the 
natural lifespan of worms (Diomede et al., 2014b). 
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Overall, these findings indicate that this approach can be applied to identify the 
molecular mechanisms are driving the heart tropism in AL amyloidosis, allowing 
a precise definition of the toxic determinants in LC. The elucidation of their 
molecular mechanisms of action can accelerate the discovery of eligible drugs 
targeting critical molecular events of the pathology (Diomede et al., 2014b, 
Diomede et al., 2014a).  
For the first time, C. elegans has been used as a “biosensor” to evaluate rapidly 
the effect of LC potentially cardiotoxic for AL patients. Soluble cardiotoxic LC 
specifically affect the pharyngeal motility of worms, similarly to Aβ protein. 
These findings indicate that C. elegans recognizes as toxicant the soluble species 
of different amyloidogenic proteins by common pathways. Furthermore, thanks to 
the small amount of human LC required to perform the analysis, this nematode-
based assay is suitable for basic research and translational applications, and it is 
also feasible for future routine clinical analysis. 
 
1.4 Metal Ions 
Metal ions are essentials for life due to their contribution to ensure the 
physiological activity of most proteins and biological processes (Kozlowski et al., 
2009, Andreini et al., 2008). Among them, iron (Fe(III)), copper (Cu(II)) and zinc 
(Zn(II)) are the most studied ones.  
Due to their high reactivity to generate ROS, metal ions are not present in blood 
plasma in the “free” form but are mainly bound to and transported across the 
cellular membranes by specific proteins. Zinc is usually bound to albumin and 
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transferrin, copper is bound to albumin and ceruloplasmin, and iron is carried by 
transferrin and stored by ferritin (Šuštar and Osredkar, 2011, MacKenzie et al., 
2008). To prevent DNA damage, lipid peroxidation and protein oxidation, cell 
death and pathological disorders, metal ion homeostasis, defined as the balance of 
uptake, storage and secretion in the different cellular compartments, is strictly 
regulated by the interplay among transporters, channels, chaperones and 
metalloregulatory sensors (Angele-Martinez et al., 2014, Bemporad and Chiti, 
2012, Roth et al., 1966, Šuštar and Osredkar, 2011, Farooqui, 2016). Severely 
dysregulation of metal ions homeostasis has been correlated to the onset and 
progression of cancer, cardiovascular and respiratory diseases, amyotrophic lateral 
sclerosis and neurodegenerative disorders including AD, Huntington’s, 
Parkinson’s and Creutzfeldt-Jakob disease (Angele-Martinez et al., 2014, Bush, 
2003). However, the molecular mechanisms triggering an imbalance of metal ion 
homeostasis in these pathologies, are not yet clear. 
Role of metal ions in AD 
Despite great efforts have been done to elucidate the pathological role of metal 
ions in different diseases, little information is currently available. Studies have 
been mainly focused on central amyloidosis whereas the involvement of metal 
ions in systemic amyloidosis has never been considered. In the past decades, 
numerous studies investigated the relationship between metal ions and the 
pathogenesis of AD. Alterations of the physiological concentrations of iron, 
copper and zinc have been detected in the brains of AD-affected patients, 
compared to controls patients (Lovell et al., 1998, Cuajungco et al., 2000). In 
particular, it was observed that metal ions can bind to Aβ protein and promote its 
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aggregation and deposition (Pithadia and Lim, 2012, Bush, 2003). Accordingly, 
increased Zn2+, Cu2+ and Fe3+ levels have been measured within the amyloid 
plaques of AD- affected patients (Table 3) (Bush, 2003, Lovell et al., 1998).  
Table 3| Metal ions’ concentrations in amyloid plaques of AD patients, compared to 
normal age-matched neuropil of control patients 
AD patients Control patients
Metal ions (µM)
340 940Fe
3+
1055 Zn
2+ 350 
Cu
2+ 390 70 
 
Adapted from (Bush, 2003, Cuajungco et al., 2000) 
 
Different studies reported conflicting data about the concentrations of metal ions 
in the different cellular compartments (Bush, 2003). The increased levels of Zn2+ 
within the amyloid plaques was accompanied by the presence of low 
concentrations of Zn2+ in the intracellular space (Atwood et al., 1999, Cuajungco 
et al., 2000), indicating that alterations of the metal ions’ distribution among 
cellular compartments, rather than an increase in their concentration, is involved 
in the onset and progression of AD (Bush, 2003).  
The toxicity of metal ions in AD is also related to their ability to promote ROS 
generation, via Fenton-like reactions (Farooqui, 2016). Aβ monomers bind Fe3+ or 
Cu2+ leading to their reduction to Fe2+ or Cu+, and the formation of Aβ radicals 
(Aβ•) (Figure 6) (Farooqui, 2016, Opazo et al., 2002). Reactive Aβ•, through the 
extraction of protons from lipids and proteins, causes the lipid peroxidation, 
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protein carbonyl modifications and the formation of nucleic acid adducts 
(Farooqui, 2016).   
In the presence of molecular oxygen (O2), Fe
2+ and Cu+ are oxidized to Fe3+ and 
Cu2+, thus generating  superoxide anion radical (O•ˉ2) and then H2O2 (Figure 6) 
(Farooqui, 2016).  
 
Figure 6|The binding of Aβ with Fe3+or Cu2+ causes the generation of H2O2 
After binding of Aβ with Fe3+ or Cu2+, toxic Aβ radicals (Aβ•) are generated and metal 
ions are reduced to Fe2+ or Cu+.  Reactive Aβ• extracts protons from lipids, proteins and 
nucleic acid causing the formation of toxic products. The interactions of reduced metal 
ions (Fe2+ or Cu+) with molecular oxygen (O2) lead to the formation of H2O2 and then 
hydroxyl radicals (OH•). Adapted from (Farooqui, 2016). 
 
 
In the presence of O•−2 or biological reductants (e.g. ascorbic acid or glutathione), 
Fe3+ and Cu2+ are reduced to Fe2+ e Cu+ which react with excess H2O2 to form 
hydroxyl radicals (OH•), via Fenton reaction (Farooqui, 2016, Huang et al., 1999).  
Fe3+ + O•ˉ2 → Fe2+ + O2   Cu2+ + O•ˉ2 →Cu++O2 
Fe2+ + H2O2→ Fe3+ + OHˉ + OH•  Cu+ + H2O2→ Cu2+ + OHˉ + OH• 
 
Zn2+ is a redox inert metal ion and thus is not directly involved in redox reactions. 
However, due its ability to bind monomeric Aβ, promoting its aggregation into 
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oligomers and plaques, it exerts a crucial role in AD pathogenesis (Farooqui, 
2016, Altamura and Muckenthaler, 2009).  
Similar interactions have been also demonstrated between metal ions and tau 
protein (Farooqui, 2016, Sayre et al., 2000), suggesting that the imbalance of 
metal ions homeostasis and oxidative stress are key elements in AD. 
 
Metal-binding compounds: clioquinol and PBT2 
Metal-binding compounds have been employed to restore metal ion homeostasis, 
thus preventing metal-induced ROS generation in several neurodegenerative 
diseases. These compounds can act as chelators or ionophores (Weekley and He, 
2017).  
Chelators have been developed to sequester and remove heavy metals after 
poisoning and then also used to reduce the systemically excess of metals in 
genetic copper and iron overload disorders (e.g. Wilson’s disease, hereditary 
haemochromatosis) (Helsel and Franz, 2015, Weekley and He, 2017). The binding 
of chelators to metal ions leads to the formation of metal complexes which are 
then excreted from the body decreasing the circulating levels of metals (Figure 7) 
(Flora and Pachauri, 2010).  
Due to their hydrophilic nature, chelating compounds cannot cross the blood-brain 
barrier and are not eligible for the treatment of neurodegenerative diseases 
(Schimmer, 2011). 
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Figure 7| Chelators and ionophores reduce metal levels through different mechanisms 
Chelators remove the excess of metals promoting their elimination. Ionophores, through 
the formation of lipophilic metal complexes, deliver metal ions into the cells. Adapted 
from (Weekley and He, 2017). 
 
At variance with chelators, ionophores act as  “metal shuttles” (Helsel and Franz, 
2015). Through the formation of lipophilic metal complexes, they deliver 
extracellular metal ions into the cells thus regulating their distribution among the 
cellular compartments, from regions of excess to regions of deficiency (Figure 7) 
(Weekley and He, 2017, Helsel and Franz, 2015). 
Among ionophores, the two 8-hydroxyquinoline derivatives clioquinol (CQ) and 
PBT2 have been intensively studied as a potential treatment for neurodegenerative 
diseases, particularly AD and Huntington’s disease.  
As shown in Figure 8, despite both compounds have the same coordination site 
for metals’ binding, they have a different substitution pattern around the quinoline 
ring. In particular, a basic side-chain has been added to PBT2 and iodine (I) at 
position 5 in CQ has been substituted with chlorine (Cl) in PBT2. These 
modifications increased the solubility of PBT2 and improved its ability to cross 
the blood-brain barrier (Adlard et al., 2008) 
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Figure 8| Structures of clioquinol and PBT2 
Clioquinol and PBT2 bind metals using oxygen, nitrogen coordination site (Barnham and 
Bush, 2014) . 
 
Until the 1970s, CQ has been used as antibiotic for the treatment of intestinal 
infections caused by amoebas (Budimir, 2011) but in 1985 due to the onset of side 
effects among the Japanese population, it was withdrawn from sale (Ayton et al., 
2017).  
The ability of CQ to bind metal ions has been then investigated. CQ is an 
ionophore able to cross the blood-brain barrier and to bind Cu2+ and Zn2+ with 
moderate affinity (1.2×10-10 M and 7×10-8 M, respectively) (Ayton et al., 2017, Di 
Vaira et al., 2004). Although it is weak interaction, it is sufficient to extract metal 
ions from extracellular Aβ aggregates and release them in the intracellular space, 
thus regulating and restoring metal neuronal homeostasis (Helsel and Franz, 2015, 
Ritchie et al., 2003, Ayton et al., 2017, Weekley and He, 2017). In 2001, Cherny 
et al. demonstrated that CQ prevents Aβ aggregation in vitro (Cherny et al., 2001). 
The pre-clinical study indicated that the daily administration of CQ for 9 weeks to 
transgenic AD mice reduced of ~49% the Aβ deposits in the brain of mice and 
counteracted their Aβ-induced memory impairment (Cherny et al., 2001, Ayton et 
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al., 2017, Grossi et al., 2009). CQ has also been used for a randomized, double-
blind, placebo-controlled pilot phase II clinical trial on AD patients (Ritchie et al., 
2003). This study showed that chronic treatment with CQ, compared to placebo, 
attenuated the cognitive impairment in patients suffering from AD. However, this 
trial was interrupted due to complications with large-scale manufacturing of the 
compound and to the onset of dyshomeostasis of vitamin B12 in the brain of CQ-
treated patients (Barnham and Bush, 2014, Ayton et al., 2017, Yassin et al., 2000).  
The second-generation 8-hydroxyquinoline compound PBT2 has been then 
developed for the treatment of AD and Huntington's disease. PBT2 is a Cu/Zn 
ionophore restoring metal homeostasis inside the cells (Adlard et al., 2008, 
Crouch et al., 2011). In vivo experiments demonstrated that the oral administration 
of PBT2 to transgenic AD mice reduced the cerebral levels of Aβ and improved 
the cognitive impairment (Adlard et al., 2008). Furthermore, PBT2 reduced the 
aggregation of mutant huntingtin in transgenic mice used as a model of 
Huntington's disease and prolonged their survival (Huntington Study Group 
Reach, 2015).  
Based on these pre-clinical findings, PBT2 has been employed for clinical studies 
on AD and Huntington's disease affected patients (Lannfelt et al., 2008, 
Huntington Study Group Reach, 2015). Results obtained from a 12 weeks-phase 
IIa clinical trial on early AD-patients, demonstrated that PBT2, orally 
administered at 250 mg/day, reduced the Aβ levels in the cerebrospinal fluid of 
AD patients and improved their memory impairment (Lannfelt et al., 2008).  A 
26weeks-phase II randomized, double-blind, placebo-controlled trial has been 
performed on Huntington's diseases. In this study no side effects have been 
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observed, indicating that PBT2, at the dose of 250 mg/day, is safe and well-
tolerated Despite the fact that some cognitive functions were improved in PBT2-
treated Huntington patients, these effects need to be confirmed in a more 
extensive study (Huntington Study Group Reach, 2015). 
 
Metal ions stimulate daf-16/FoxO signalling 
Transition metal ions and oxidative stress are reported to regulate the expression 
of the forkhead box O (FoxO) transcription factors in insulin/insulin growth factor 
(IGF)-1 signalling (IIS) pathway (Eckers and Klotz, 2009). IIS pathway is highly 
conserved from C. elegans to mammals (Eckers and Klotz, 2009). IIS pathway is 
highly conserved from C. elegans to mammals (Lin et al., 2001) and it is involved 
in the regulation of different cellular processes including proliferation, apoptosis, 
metabolism, ageing, longevity, proteostasis and stress resistance (Hay, 2011).  
In the presence of a lower concentration of insulin or insulin-like molecules, 
FoxO in its unphosphorylated form is localized in the nucleus of the cells and 
promotes the transcription of its target genes (Lee and Dong, 2017). When insulin 
or insulin-like molecules increased, the binding to the insulin receptor (InsR) 
results in the phosphorylation and activation of phosphoinositide 3-kinases (PI3K) 
and the serine/threonine kinase Akt (Eckers and Klotz, 2009) (Figure 9). After 
activation, Akt phosphorylates nuclear FoxO thus promoting its exclusion into the 
cytoplasm and causing the down-regulation of its target genes (Hay, 2011, Eckers 
and Klotz, 2009). Transition metal ions, such as copper and zinc, can act as 
insulin- like molecules able to bind to InsR and promote the nuclear exclusion of 
FoxO into the cytoplasm (Eckers and Klotz, 2009) . 
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As stated before, the IIS pathway plays a crucial role also in protecting cells from 
oxidative stress (Lee and Dong, 2017). In 2004, Essers et al. demonstrated that the 
H2O2-induced oxidative stress leads to the c-Jun–N-terminal kinase (JNK)-
mediated phosphorylation of threonine 447 and threonine 451 in FoxO (Essers et 
al., 2004). Phosphorylated FoxO translocated and, to improve cell resistance to 
stress, activated the transcription of genes coding for anti-oxidative enzymes, 
including SOD, catalase and glutathione peroxidase (Figure 9) (Essers et al., 
2004).  
 
Figure 9| Schematic representation of the IIS pathway in vertebrates 
The binding of insulin to its receptor activates the PI3K and Akt kinases, leading to the 
nuclear exclusion of FoxO into the cytoplasm. Oxidative stress promotes an alternative 
pathway through the activation of JNK which induced FoxO phosphorylation and its 
nuclear translocation. This results in the activation of transcription of genes coding for 
anti-oxidant proteins. Adapted from (Hay, 2011). 
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For a long time, amyloid deposits were thought to be causative agents in the 
degenerative process (Roth et al., 1966). Recent studies suggest that the pre-
fibrillar, oligomeric assemblies of the amyloidogenic proteins, more than fibrils, 
are mainly responsible of the toxicity and organ dysfunction observed in patients 
affected by amyloid-related diseases (Bemporad and Chiti, 2012, Treusch et al., 
2009).  
The research program of my PhD was aimed to elucidate the molecular 
mechanisms underlying the ability of C.elegans’ pharynx to recognize as toxicant 
the soluble, pre-fibrillar assemblies of the amyloidogenic proteins, particularly LC 
able to cause heart damage in patients suffering from AL amyloidosis.  
Based on the knowledge that the in vivo toxicity exert by cardiac LC are 
specifically related to their ability to generate higher amount of ROS and promote 
oxidative damage, the aims of the work described in this thesis were to identify 
the molecular mediators driving ROS production and investigate about the 
proteins/pathways that are deterministically involved in protein-related 
pharyngeal damage.  
The elucidation of the molecular mechanisms occurring in AL amyloidosis will be 
crucial to design an effective pharmacological strategy aimed at interrupting the 
vicious cycle of oxidative stress, blocking the mechanism of heart damage thus 
improving life expectancy of AL patients with cardiac involvement. 
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3.1 Media, solutions and buffers used for C. elegans studies 
All media, solutions and buffers were sterilized before the use and diluted using 
sterile ddH2O. 
Nematode Growth Medium (NGM)-Agar 
NaCl       3.0 g  
Bacteriological Agar    17.0 g  
Bactopeptone      2.5 g  
H2O to 1 litre 
After sterilization in autoclave, the following solutions were added: 
Cholesterol (5 mg/ml in EtOH)   1.0 ml 
1M CaCl2       1.0 ml 
1M MgSO4      1.0 ml 
1M potassium phosphate, pH 6   25.0 ml 
M9 buffer 
KH2PO4      6.0 g 
Na2HPO4      6.0 g 
NaCl      5.0 g 
1M MgSO4      1.0 ml 
H2O to 1 litre. 
1X Bleach solution 
5% Bleach      1.0 ml 
10N NaOH      250 µl 
Materials and methods 
  56 
 
H2O      3.75 ml 
 1X Egg buffer 
NaCl      6.9 g 
KCl       3.6 g 
MgCl2      190.4 g 
1M Hepes, pH 7.3     25 ml 
H2O to 1 litre. 
 
3.2 Immunoglobulin light chains purification 
Urines were obtained from patients during routine diagnostic procedures 
performed at the Amyloid Research and Treatment Centre, Foundation IRCCS 
Policlinico San Matteo (Pavia, Italy). The institutional review board approved the 
acquisition, storage, and use of biological samples for research purposespproved 
by the institutional review board. Written informed consent was received from 
participants before inclusion in the study. The presence of tissue amyloid deposits 
and amyloid organ involvement were defined according to the International 
Consensus Panel Criteria (Gertz et al., 2005). LC cardiotoxicity has been 
evaluated by clinical, echocardiography, and biochemical parameters. Non-
amyloidogenic LC from myeloma patients were used as controls. All LC included 
in the study were k isotype, which represents about the 75% of amyloidogenic 
LC. Human monoclonal LC have been isolated from urine (BJ) and by 
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production, as recombinant proteins (Perfetti et al., 1996, Rognoni et al., 2013), 
were provided by Amyloid Research and Treatment Centre, Foundation IRCCS 
Policlinico San Matteo (Pavia, Italy). Overall, seven LC were obtained (six BJ 
and one recombinant) (Diomede et al., 2017). 
 
3.3 Hydrogen peroxide determination  
To determine the role of metal ions in AL amyloidosis, cardiotoxic (H7-BJ) and 
myeloma (MM2-BJ) proteins (1 mg/ml) in 10 mM phosphate-buffered saline 
(PBS), pH 7.4, have been incubated in the presence or absence of chelex 100 
chelating resin (5 mg/ml, Bio-Rad Laboratories, München, Germany) for 1 h at 
4°C with shaking, according to the manufacturer’s instructions. In the same 
experimental conditions, PBS and bidistilled water have been incubated with 
chelex and used as controls for the experiments. After incubation, all samples 
have been centrifuged at 8700 x g for 5 min at 4°C. Supernatants have been 
collected, and the protein content has been determined (Bio-Rad Laboratories 
GmbH, München, Germany). 
The ability of LC to generate H2O2 has been then evaluated by using the Amplex
® 
Red Hydrogen Peroxide/Peroxidase Assay Kit (Catalog no. A22188; Molecular 
Probes, Life Technologies, Thermo Fisher, Milan, Italy), according to the 
manufacturer’s instructions. Proteins have been diluted at 100 µg/ml with 10 mM 
PBS, pH 7.4 in a volume of 50 µl and moved into a 96-well black plate. Fifty µl 
of 100 µM Amplex® Red reagent and 0.2 U/ml HRP working solution has been 
added to each microplate well-containing samples (final concentration of protein 
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50 µg/ml). To determine the amount of H2O2 produced by proteins, a standard 
curve from 0 to 10 µM H2O2 in 1X Reaction Buffer has been prepared just before 
use. 
Also, 10 µM H2O2 solution in 1X Reaction Buffer was used as a positive control, 
and 1X Reaction Buffer without H2O2 was used as a negative control. Additional 
controls included 10 mM PBS (pH 7.4) and bidistilled water, incubated or not 
with chelex.  
All samples have been incubated at room temperature for 30 minutes, protected 
from the light. The fluorescence has been then measured at different time using 
Tecan Infinite M200 microplate reader (Tecan, Austria) at an excitation 
wavelength of 563 nm and an emission wavelength of 587 nm. 
Additional experiments have been carried out incubating proteins in the presence 
of 50 µM CuCl2, 50 µM ZnCl2, 50 µM FeCl2, 25 µM CQ (dissolved in DMSO at 
250 µM; Sigma Aldrich, MO), or 2 nM PBT2 (dissolved in absolute ethanol at 
250 µM; Prana Biotechnology Ltd, Parkville, Australia). CuCl2, ZnCl2, FeCl2, 
CQ, and PBT2 alone have been used as controls. To investigate the role of thiols 
in driving metal-induced toxicity, proteins have been incubated with 
iodoacetamide (1:10 molar ratio) for 3 h at 20°C (Winterbourn and Carrell, 1977). 
Iodoacetamide alone was used as a control.  
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3.4 C. elegans studies 
Commercial strains 
N2 ancestral worms (wild type) and transgenic CL2070, CF1553 and TJ356 
nematodes were used. They were all obtained from the Caenorhabditis elegans 
Genetic Center (CGC; University of Minnesota, Minneapolis, USA) and 
propagated at 20°C on solid nematode growth medium (NGM) seeded with OP50 
Escherichia coli (E.coli) (CGC; University of Minnesota, Minneapolis, USA) for 
food. The genotype and the description of the transgenic strains are summarized 
in Table 4. 
 
Table 4| Summary of the transgenic strains used for the experiments.  
Strain 
name 
Construct details Use 
CL2070 
dvIs70 [hsp-16.2p::GFP + rol-6(su1006)]  
Nematodes express the green fluorescent protein 
(GFP) under control of the hsp-16.2 promoter (Link 
et al., 1999). 
To visualize HSP-16.2 
expression after 
oxidative stress (Link 
et al., 1999). 
 
CF1553 
muIs84 [(pAD76) sod-3p::GFP +    rol-6(su1006)] 
Nematodes express GFP under control of the sod-3 
promoter (REF). 
To visualize SOD-3 
expression after 
oxidative stress 
(Libina et al., 2003). 
TJ356 
zIs356 [daf-16p::daf-16a/b::GFP +  rol-6(su1006)] 
Nematodes express the full length daf-16 fused to 
GFP.  DAF-16/GFP expression is under the control 
of the daf-16 promoter (Lin et al., 2001). 
To monitor the 
translocation of DAF-
16 (Hartwig et al., 
2009). 
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dvIs70= Integrated (Is) transgene (“dv” allele designation from the Reiner Lab; the 70th 
allele generated in the Reiner Lab). muIs84= Integrated (Is) transgene (“mu” allele 
designation from the Wightman Lab; the 84th allele generated in the Wightman Lab). 
zIs356= Integrated (Is) transgene (“z” allele designation from the Johnson Lab; the 356th 
allele generated in the Johnson Lab). rol-6= dominant collagen mutation that causes 
animals to roll and move in circles. su1006= (“su” allele designation from the Epstein 
Lab; the 1006th allele generated in the Epstein Lab).  
 
Synchronization of C. elegans strains 
To prepare age-synchronized nematodes, adult animals were collected with M9 
buffer into 50 ml tube, centrifuged at 290 x g for 3 minutes at room temperature 
and washed 4 times to eliminate bacteria. After that supernatant was removed, 
worms were moved into 15 ml tube and resuspended in 5 ml of bleach solution 
prepared immediately before use. Nematodes were incubated on orbital shaking at 
room temperature for 5-10 minutes until the worms appeared damaged and the 
eggs released from the adult bodies.   
Eggs were washed 4 times with 1X egg buffer, then resuspended in 1 ml of 1X 
egg buffer and left overnight on orbital shaking at 20°C in the absence of bacteria. 
In these conditions, due to food deprivation, the newly hatched L1 larvae cannot 
evolve to the next developmental stages. Next day, L1 larvae were moved to fresh 
NGM plates seeded with OP50 E. coli for food. 
 
Protein administration and pharyngeal pumping rate 
L3 age-synchronized nematodes were collected with M9 buffer, centrifuged, and 
washed twice with 10 mM PBS, pH 7.4 to eliminate bacteria avoiding any 
potential interference between bacteria and the LC (Diomede et al., 2014a). 
Worms were incubated 2 hours with 100 µg/ml BJ or recombinant LC (100 
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worms/100 µl) in 10 mM PBS, pH 7.4. Control worms were incubated with 10 
mM PBS, pH 7.4 (vehicle) only. After incubation on orbital shaking, worms were 
transferred onto fresh NGM plates seeded with OP50 E. coli. The pharyngeal 
pumping rate, measured by counting the number of times the terminal bulb of the 
pharynx contracted over a 1-minute interval, was scored 20 h later (Diomede et 
al., 2014a).  
To evaluate the role of metal ions in LC-induced toxicity, additional experiments 
were carried out by feeding worms for 2 h with 100 µg/ml of LC alone or with 5 
mM NAC (Sigma-Aldrich) or 2050 µM TETRA (Sigma-Aldrich) in 10 mM PBS, 
pH 7.4; 5 mg/ml chelex in 10 mM PBS, pH 7.4; 10 µM EDTA (Sigma Aldrich) in 
metal-free water (Sigma Aldrich), 0–25 µM CQ, or 0–25 nM PBT2 dissolved as 
described above; 50–100 µM copper (from CuCl2) in metal-free water, 50–100 
µM zinc (from ZnCl2) in metal-free water, 50–100 µM iron (from FeCl2) in metal-
free water. Control worms were exposed, in the same experimental conditions, to 
metal ions alone. Although metals’ concentrations are well above the 
physiological levels in humans, they are not toxic to worms (Boyd et al., 2003, 
Rebolledo et al., 2011). However, higher doses of chelex, EDTA, CQ, and PBT2 
were toxic to nematodes (Harrington et al., 2012, Imbert et al., 1990).  
To investigate the role of H2O2 in LC-induced pharyngeal dysfunction, additional 
experiments were carried out using 1 mM H2O2 for 30 min, alone, or together 
with 5 mg/ml chelex, 25 µM CQ, or 2 nM PBT2. Furthermore, 1 mM H2O2, 100 
µg/ml cardiotoxic and myeloma LC were diluted in 50 mM phosphate buffer, pH 
7.0, and incubated with 100 U/ml catalase (Sigma Aldrich) for 15 min at room 
temperature in dark conditions before nematodes’ administration. Worms were 
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then fed with these solutions (100 worms/100 µl) for 30 min on orbital shaking in 
dark conditions and then moved onto fresh NGM plates seeded with bacteria. The 
pharyngeal pumping rate was measured 2 h later.  
The combined effect of TETRA and metal binding compounds were then 
investigated feeding nematodes (100 worms/100 µl) with 100 µg/ml H7-BJ alone 
for 2 h and then treated for 30 min with CQ (25 µM), PBT2 (0.5–2 nM), 20 µM 
TETRA alone, or together with 0.5–2 nM PBT2. Worms were then transferred 
onto NGM plates seeded with OP50 E. coli in the presence of the same drug 
concentration, and the pharyngeal pumping rate was scored 20 h later.  
Control worms were exposed, under the same conditions, to the drugs alone or the 
vehicle. 
 
Life span studies 
N2 nematodes (100 worms/100 μl), at the L3 larval stage, were fed for 2 h 100 
μg/ml of cardiotoxic LC in presence or absence of 25 μM CQ or 2 nM PBT2. 
Worms were then moved onto fresh NGM plates seeded with E. coli in the 
presence of the same drug concentration. Control worms were exposed, under the 
same conditions, to the vehicle or the drugs alone. After 20 h nematodes were 
transferred to fresh NGM plates seeded with bacteria and the number of live 
worms was scored (considered as day 0). To avoid overlapping generations, the 
worms were then transferred every day until they stopped laying eggs. Fresh 2 nM 
PBT2 was daily added to PBT2-treated worms. The number of live worms was 
determined for each consecutive day until all worms were dead. 
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Mitochondrial membrane potential 
N2 nematodes were fed with 100 µg/ml cardiotoxic or myeloma proteins (100 
worms/100 µl) in 10 mM PBS, pH 7.4. Negative control worms were incubated 
with 10 mM PBS, pH 7.4 (vehicle) alone and positive control worms were 
incubated with 1mM H2O2. Nematodes were incubated 2h on orbital shaking at 
room temperature in dark conditions and then transferred on fresh NGM plates 
seeded with OP50 E. coli, pre-treated for 2 h with 20 µM TMRM (Molecular 
Probes, Thermo Fisher Scientific). After 24 h, worms were collected with M9 
buffer, centrifuged at 2000 x g for 5 min and immobilized with 20 mM 
levamisole. Nematodes were immediately used for microscopic examination with 
an inverted fluorescent microscope (IX-71 Olympus) equipped with a CCD 
camera. Images of the pharynges were taken at 40X magnification with a TRITC 
filter set (Olympus). 
 
Mitochondrial production of ROS 
Feeding worms evaluated the effect of LC on mitochondrial oxidant burden with 
MitoSOX Red (Molecular Probes, Italy) (Molecular Probes, Italy) (Diomede et 
al., 2014a). Worms at the L3-L4 larval stage were incubated for 2 h with 100 
μg/ml cardiotoxic and myeloma protein in 10 mM PBS, pH 7.4 in the absence or 
presence of 25 μM CQ or 2 nM PBT2. Negative control worms were fed vehicle 
alone whereas positive controls were fed 1 mM H2O2 for 30 min. The effect of 
drugs alone was also determined. Experiments were also carried out incubating 
worms with 1 mM H2O2 for 30 min, alone, or together with 25 µM CQ, or 2 nM 
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PBT2. Nematodes were then transferred to NGM plates seeded with fresh bacteria 
as food and 10 μM MitoSOX Red. After 20 h, nematodes were transferred to fresh 
NGM plates seeded with OP50 and left for 1 h, so that residual dye could be 
washed out from the pharynx lumen. Nematodes were paralyzed by adding 20 
mM levamisole (Sigma-Aldrich) and left for 30 min on orbital shaking in dark 
conditions. Nematodes were then centrifuged at 2000 x g for 5 min at room 
temperature and fixed in 4% paraformaldehyde for 24 h at 4°C. Worms were then 
mounted on slides for microscopy and observed by epifluorescence using an 
inverted fluorescent microscope (IX-71 Olympus) equipped with a CDD camera. 
 
Transmission electron microscopy analysis 
N2 worms fed 100 μg/ml cardiotoxic LC or myeloma proteins (100 worms/100 
μl) in 10 mM PBS, pH 7.4, alone or with 5 mM NAC, 50 μM TETRA, 25 μM CQ 
or 2 nM PBT2. Control worms were incubated with vehicle alone (Vehicle) only. 
After 2 h of incubation on orbital shaking, worms were transferred onto NGM 
plates seeded with OP50 E. coli in the presence of the same drug concentration. 
After 20 h, nematodes were picked, washed in 10 mM PBS, pH 7.4, and fixed 
with 2% glutaraldehyde in 0.12 M phosphate buffer, pH 7.4. Worms were then cut 
open at the level of the second bulb of the pharynx, to improve access to the 
fixative. After post-fixation at room temperature overnight, samples were 
incubated in a solution of 1% OsO4 and 1.5% ferrocyanide in 0.12 M cacodylate 
buffer (ferrocyanide-reduced OsO4) at room temperature for 1 h, then 0.3% 
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thiocarbohydrazide in H2O for 5 min, and finally 2% OsO4 in 0.12 M cacodylate 
buffer for 1 h.  
C. elegans pharynx was then placed into 2% agarose gel, and small cubes were 
cut and dehydrated in graded series of ethanol for 10 min each, cleared in 
propylene oxide and embedded in Epoxy medium (Epon 812 Fluka) and 
polymerized at 60°C for 72 h. From each sample, one semithin (1 μm) section was 
cut with a Leica EM UC6 ultramicrotome and mounted on glass slides for light 
microscopic inspection. Ultrathin (60-80 nm thick) sections of areas of interest 
were obtained, counterstained with uranyl acetate and lead citrate, and examined 
with an Energy Filter Transmission Electron Microscope (EFTEM, ZEISS 
LIBRA® 120) equipped with a YAG scintillator slow-scan CCD camera. 
TEM analysis was performed in collaboration with Dr. Fabio Fiordaliso, Head of 
the Bio-imaging Unit, Department of Cardiovascular Research, Istituto di 
Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.  
 
DAF-16 translocation assay and pharyngeal expression of heat-shock protein 
(HSP)-16.2 and manganese superoxide dismutase (SOD)-3 
DAF-16/GFP nuclear translocation was evaluated in TJ356 nematodes. 
Pharyngeal expression of HSP-16.2 and SOD-3 was determined in CL2070 and 
CF1553 worms, respectively.  
Age-synchronized nematodes at L3 larval stage were incubated for 2 h at 20°C 
with 100 μg/ml cardiotoxic (H7-BJ) or myeloma (MM2-BJ) protein (100 
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worms/100 μl) in 10 mM PBS, pH 7.4, in the absence or presence of 25 μM CQ, 2 
nM PBT2, 50 μM TETRA and 5 mM NAC. Control worms were incubated with 
10 mM PBS, pH 7.4, (vehicle) or drugs alone. After 2-20 h, nematodes were 
paralyzed by adding 20 mM levamisole, centrifuged at 2000 x g for 5 min at room 
temperature, and fixed in 4% paraformaldehyde in 10 mM PBS, pH 7.4, for 24 h 
at 4°C in dark conditions. Nuclear translocation of DAF-16 was visualized with 
an inverted fluorescent microscope (IX-71 Olympus) equipped with a CDD 
camera. Organisms were scored as positive for nuclear localization when green 
foci were observed throughout the entire body from head to tail and as cytosolic 
when DAF-16/GFP was diffused.  
The number of worms with each level of translocation was counted (n=100 
worms/ condition). The assay was repeated at least four times. 
To prove the nuclear localization of activated DAF-16/GFP, nuclear 
counterstaining was performed with 2’-[4-ethoxyphenyl]-5-[4-methyl-1-
piperazinyl]-2,5’-bi-1H-benzimidazole trihydrochloride trihydrate (Hoechst 
33342; Thermo Fisher Scientific). Nematodes were fed 100 µg/ml of cardiotoxic 
(H7-BJ) LC (100 worms/100 µl) in 10 mM PBS, pH 7.4. Control worms were 
incubated with 10 mM PBS, pH 7.4 (vehicle) only. Worms were incubated 2 h 
with orbital shaking and then paralyzed by adding 20 mM levamisole. After 
centrifugation at 2000 x g for 3 min, nematodes were fixed in 4% 
paraformaldehyde for 24 h at 4°C on orbital shaking in dark conditions. 
Nematodes were then centrifuged at 2000 x g for 3 min, washed twice with 10 
mM PBS, pH 7.4, and resuspended in 0.5 ml of 125 mM Tris- HCl solution, pH 
7.4, containing 1% Triton X- 100 and 5% β-mercaptoethanol. After overnight 
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incubation at 4°C, worms were washed with 10 mM PBS, pH 7.4 and incubated at 
room temperature for 30 min in 0.5 ml of Hoechst (1 mg/ml in 10 mM PBS, pH 
7.4). Nuclear translocation of DAF-16 and Hoechst was visualized at 40X 
magnification with a GFP and a UV filter, respectively, with an inverted 
fluorescent microscope (IX-71 Olympus) equipped with a CCD camera. At least 
10 worms were photographed per group. 
Images for HSP-16.2 and SOD-3 GFP-expression in the pharynx of worms were 
acquired using the same exposure settings. Sampling images of different animals 
calculated average pixel intensity values. Mean pixel intensity for each 
experimental group was calculated using Cell-F software (Olympus). For each 
experiment at least 25 worms were examined for each strain/condition. Each 
experiment was repeated 3 times. 
 
3.4 Circular dichroism (CD) spectroscopy and thermal stability 
analysis 
Far-UV circular dichroism (CD) spectra of cardiotoxic LC (H7-BJ) and myeloma 
(MM2-BJ) proteins treated or not with 5 mg/ml chelex, 25 µM CQ, or 2 nM 
PBT2. All samples, at a protein concentration of 0.4 mg/ml in 50 mM sodium 
phosphate, pH 7.4, were incubated overnight at room temperature. Far-UV CD 
measurements were performed at 25°C in 50 mM sodium phosphate, pH 7.4, with 
a Jasco J-700 spectropolarimeter (Jasco Europe, Cremella, Italy) using a quartz 
cuvette with a path length of 1 mm. Scans were conducted from 250 to 200 nm at 
a speed of 100 nm/min with a spectral band width of 2 nm, a sensitivity of 20 
degrees, and response time of 1 s. The α-helical and β-sheet contents were 
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calculated with K2D, CDSSTR, and CONTIN software applications CD. CD 
spectra represent the average of 10 scans. Data are shown as mean residue 
ellipticity (MRE, deg cm2 dmol-1) as a function of wavelength.  
Melting data were recorded at 202 nm to monitor β-sheet unfolding on sample 
heating from 37°C to 80°C. Analyses were performed in a 1 mm path length 
quartz cuvette, temperature slope of 1°C/min, band width of 2 nm, data pitch of 
0.2° C, and response time of 2 s. The thermal melt value (Tm) for each condition 
was calculated at the midpoint of the unfolding transition.  
CD analysis was performed in collaboration with Dr. Paola Rognoni, at the 
Amyloid Research and Treatment Centre, Foundation IRCCS Policlinico San 
Matteo, Pavia, Italy. 
 
3.5 Statistical analysis 
Data were analyzed using GraphPad Prism 7.0 software (CA, USA) by an 
independent Student’s t-test, one-way and two-way ANOVA and Bonferroni’s 
post-test analysis. The values of IC50 and median survival were determined using 
Prism version 6.0 for Windows (GraphPad Software, CA, USA). A p-value <0.05 
was considered statistically significant. 
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4.1 Cardiotoxic LC affect pharyngeal motility through ROS 
generation  
Cardiotoxic LC specifically impair the pharynx of C. elegans through ROS 
generation, particularly within mitochondria (Diomede et al., 2014a). To evaluate 
the ability of cardiotoxic and myeloma proteins to promote ROS generation, 
amplex red has been employed in cell-free conditions as a fluorescent reporter. As 
reported in Figure 10, cardiotoxic LC generated significantly higher levels of 
ROS, particularly H2O2, compared to myeloma ones (725 ± 55.8 vs 278 ± 61.9 
fluorescence intensity [FI] value for cardiotoxic LC and myeloma, respectively, 
p<0.01) (Diomede et al., 2017). 
 
Figure 10| Detection of reactive oxygen species generated by cardiotoxic LC  
Detection of H2O2 produced by cardiotoxic LC and myeloma by Amplex red. Data are 
expressed as mean ± SE of fluorescence intensity (FI), n=6, **p<0.01 vs cardiotoxic LC, 
one-way ANOVA and Bonferroni’s post hoc test. Adapted from (Diomede et al., 2017). 
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Similar results were obtained using different cardiotoxic and myeloma proteins 
derived from unrelated germline gene confirming that the ability of cardiotoxic 
LC to promote ROS generation is not linked to a specific amino acid sequence 
(Diomede et al., 2017).  
To elucidate the role of H2O2 in driving the pharyngeal dysfunction caused by 
cardiotoxic LC, catalase has been employed (Figure 11). Catalase is an 
oxidoreductase enzyme that, through the hydrolyzation of H2O2 into oxygen and 
water, scavenges hydrogen peroxide when it is present in high concentrations 
(Djordjevic, 2004). 
To this end, worms were fed with cardiotoxic and myeloma proteins previously 
incubated for 15 min with 100 U/ml of catalase. In these experimental conditions, 
catalase completely abolished the toxicity induced by exogenous H2O2, used as a 
positive control, and counteracted the pharyngeal dysfunction caused by 
cardiotoxic LC (Figure 11). No changes were observed with myeloma-fed worms 
(Figure 11) (Diomede et al., 2017). 
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Figure 11| Effect of catalase on cardiotoxic LC-induced pharyngeal dysfunction 
Worms were fed for 30 min with 100 µg/ml cardiotoxic LC or myeloma, or 1 mM H2O2 
(used as positive control) previously incubated or not with 100 U/ml catalase for 15 min 
at room temperature in dark conditions. Control worms received 50 mM phosphate 
buffer, pH 7.0 (Vehicle). Pumping rate as mean pumps/min ± SE (3 independent assays, 
n= 30 worms/assay). **p<0.01 vs Vehicle, °°p<0.01 vs the corresponding H2O2 or 
cardiotoxic LC not treated with catalase, one-way ANOVA, and Bonferroni’s post hoc 
test (Diomede et al., 2017).  
 
To investigate the effects of ROS on pharyngeal subcellular compartments, 
transmission electron microscopy (TEM) analyses were performed after LC 
administration (Figure 12).  
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Figure 12| ROS-induced cardiotoxic LC severely disrupt C. elegans pharyngeal 
ultrastructure 
Representative images of worm’s pharynx obtained from the ultrastructural analysis by 
TEM in C. elegans fed for 2 h with (A) Vehicle, (B) myeloma protein and (C) cardiotoxic 
LC. Images showed two pharyngeal muscles (pm) separated by a marginal cell (mc), 
placed at the corner of the pharyngeal channel (ch). Arrows indicate mitochondria. Scale 
bar, 500 nm. Pharyngeal muscles of worms fed cardiotoxic LC resulted in damage to 
mitochondria, which exhibited a clustering pattern, irregular shape, swelling, and 
massive disruption of the internal components (i.e., cristae). Marginal cells, which 
contain many mitochondria due to their active role in contractile motor function, were 
severely compromised and myofilaments connected to the marginal cells, which were 
perfectly aligned in vehicle-fed worms, were deranged.  Adapted from (Diomede et al., 
2017).  
 
Due to the vital role of mitochondria in providing energy for contractile activity, 
the effects of ROS on these organelles have been evaluated. As reported in Figure 
12 B, cardiotoxic LC-fed worms, showed severe pharyngeal ultrastructure 
alterations, particularly in muscles and mitochondria, compared with vehicle-
treated nematodes (Figure 12 A). In particular, mitochondria were enlarged and 
also the cristae, formed by the internal membrane, were almost lost entirely 
(Figure 12 B). No alterations in mitochondria, both in size and morphology, have 
been detected when worms were fed with myeloma proteins (Figure 12 C) 
(Diomede et al., 2017). 
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Moreover, tetramethylrhodamine methyl ester (TMRM) was then used to evaluate 
the effect of cardiac and myeloma proteins on mitochondrial membrane potential. 
Under physiological conditions, TMRM accumulates in healthy mitochondria 
with intact membrane potentials revealing a bright signal. On the contrary, 
unhealthy mitochondria lose their membrane potential causing a reduction of the 
TMRM signal.  
In our experimental conditions, cardiotoxic LC-fed worms, similarly to the H2O2-
fed worm, showed a reduction of mitochondrial membrane potential, 
demonstrating that the morphological alterations caused by cardiotoxic LC were 
accompanied by impaired mitochondrial function (Figure 13). No modifications 
of the mitochondrial membrane potential have been detected in myeloma-fed 
worm (Figure 13 C) (Diomede et al., 2017).  
 
 
Figure 13| Effect of cardiotoxic LC on pharyngeal mitochondrial membrane potential 
Representative images illustrate the TMRM accumulation, which appeared brighter in 
healthy pharyngeal cells of vehicle-fed worms (A), and was lost after the treatment with 
cardiotoxic LC (B), but not myeloma protein (C), as an indication of depolarization of the 
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mitochondrial membrane potential. A similar effect was observed with H2O2 used as 
positive control (D). Scale bar, 50 µm (Diomede et al., 2017). 
 
To establish if the functional and structural alterations caused by cardiotoxic LC 
were ascribed to a specific protein or intrinsic features of cardiac LC, different 
cardiotoxic LC derived from unrelated germline gene were used. Results obtained 
in the same experimental conditions revealed similar toxic effects for all the 
cardiac proteins considered in the study, with no restriction to a particular 
germline gene or set of genes (Diomede et al., 2017). 
 
4.2 Cardiotoxic LC regulate genes involved in oxidative stress 
resistance 
The effects of ROS generation on oxidative stress pathways have been then 
evaluated.  
In C. elegans, oxidative stress conditions promote the phosphorylation and 
translocation of a FOXO gene, called daf-16, from cytosol to nucleus of the cell. 
This leads to the transcription of different genes involved in oxidative stress 
response and survival, including sod-3 and hsp 16.2 (Back et al., 2012, Hartwig et 
al., 2009, Mukhopadhyay et al., 2006). 
To determine if the translocation of DAF-16 mediates the toxicity caused by 
cardiac LC, transgenic TJ356 C. elegans nematodes expressing daf-16 fused with 
the green fluorescent protein (DAF-16/GFP) - under the control of the daf-16 
promoter - has been used (Hartwig et al., 2009).  
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When worms were fed with vehicle or myeloma proteins, DAF-16 is detected 
mainly in the cytosol of the cells (Figure 14 A-C-D). The exposure to high 
amounts of ROS generated by cardiac LC modulated the FOXO signalling 
pathway promoting the nuclear translocation of DAF-16. This process is 
detectable as the appearance of condensed green foci in the body of the worms 
(Figure 14 B-C-D). Similar results were obtained when worms were fed with 
exogenous H2O2 (Appendix 2 A) (Diomede et al., 2017). 
 
Figure 14| Cardiotoxic LC promote DAF-16 translocation from cytoplasm to nucleus 
in TJ356 transgenic worms 
(A, B) Image of DAF-16/GFP expression in (A) control vehicle-fed and (B) cardiotoxic 
LC- fed worms. (C, D) The subcellular distribution of DAF-16 expression in worms fed 2 
h: vehicle, 100 µg/ml cardiotoxic or myeloma LC. According to DAF-16 localization, 
worms were divided into two phenotypes, including “cytosolic” and “nuclear”. The 
percentage of DAF-16 localization concerning vehicle-fed worms was calculated based 
on three experiments, n=100.  Mean ± SE. **p<0.01 vs vehicle, one-way ANOVA, and 
Bonferroni’s post hoc test. Adapted from (Diomede et al., 2017). 
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Furthermore, the nuclear localization of DAF-16 has been confirmed by co-
localization experiments, carried out using a blue fluorescent dye specific for 
nuclei (Figure 15) (Diomede et al., 2017). 
After translocation in the nucleus, DAF-16 activates the transcriptions of proteins 
involved in the adaptive responses of the antioxidant defence system that protects 
against oxidative stress (Hartwig et al., 2009).  
To demonstrate the activation of this defence system after cardiotoxic LC-feeding, 
the expression of two genes transcriptionally regulated by DAF-16 has been 
evaluated. In particular, the involvement of the HSP 16.2, acting as a ROS sensor 
and also affects the lifespan of worms (Hartwig et al., 2009), and the activity of 
the enzyme SOD-3, a mitochondrial enzyme converting superoxide into less toxic 
hydrogen peroxide and oxygen, was investigated. C. elegans expresses five SOD 
enzymes. Among them, both SOD-2 and SOD-3 are Mn-SOD enzymes localised 
in the mitochondria of cells (Back et al., 2012, Hunter et al., 1997, Moreno-
Arriola et al., 2014).  
However, only sod-3 is upregulated explicitly by ROS through daf-16 
translocation, whereas sod-2 is activated during normal developmental stages. 
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Figure 15| Co-localization of nuclear staining and DAF-16/GFP in transgenic TJ356 
worms fed cardiotoxic LC 
Representative images depict in (A) the blue fluorescence of nuclear staining and in (B) 
the green fluorescence provided by DAF-16/GFP labelling. The nuclear localization of 
DAF-16/GFP was demonstrated by the co-localization of the two stainings in panel (C). 
Scale bar = 100 µm (Diomede et al., 2017).  
 
To confirm the activation of HSP-16.2 after cardiac LC-feeding, transgenic 
CL2070 worms, expressing GFP under the control of hsp-16.2 promoter, has been 
used (Hartwig et al., 2009). As shown in Figure 16, cardiotoxic LC, induced a 
significant increase in HSP-16.2 signal in the pharynx of worms, similar to that 
caused by the H2O2 administration (Appendix 2 B). No effects have been detected 
in myeloma-fed worms (Figure 16) (Diomede et al., 2017). 
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Figure 16| Cardiotoxic LC induce the pharyngeal expression of HSP-16.2 
Transgenic worms were fed for 2 h with (i) Vehicle, (ii) 100 µg/ml myeloma or (iii) 100 
µg/ml cardiotoxic LC. (A) Images of HSP-16.2 expression as overlays of GFP 
fluorescence and light microscopy in CL2070 transgenic worms. Scale bar, 50 µm. (B) 
Quantified GFP intensity in CL2070. FI in each group was calculated as mean grey 
value ± SE based on three experiments, n = 25. **p<0.01 vs Vehicle, one-way ANOVA, 
and Bonferroni’s post hoc test. Adapted from (Diomede et al., 2017). 
 
In the same experimental condition, the activation of SOD-3 has been then 
investigated using transgenic CF1553 worms, expressing GFP under the control 
of sod-3 promoter (Anbalagan et al., 2012). As reported in Figure 17, cardiotoxic 
LC-fed worms, but not myeloma-ones, caused the activation of SOD-3 protein 
expression in the pharynx of nematodes. Similar effects have been observed when 
nematodes were fed with exogenous H2O2 (Appendix 2 B) (Diomede et al., 2017). 
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Figure 17| Cardiotoxic LC induce the pharyngeal expression of SOD-3 
Transgenic worms were fed for 2 h with (i) Vehicle (10 mM PBS, pH 7.4), (ii) 100 µg/ml 
myeloma or (iii) 100 µg/ml cardiotoxic LC. (A) Images of SOD-3 expression as GFP 
fluorescence (arrows) in CF1553 transgenic worms. Scale bar, 50 µm. (B) Quantified 
GFP intensity in CF1553 worms in response to treatments. FI in each group was 
calculated as mean grey value ± SE based on three experiments, n=25. **p<0.01 vs 
Vehicle, one- way ANOVA, and Bonferroni’s post hoc test. Adapted from (Diomede et al., 
2017). 
 
 
These findings indicated that the specific ability of cardiotoxic LC to damage sub-
cellular pharyngeal structures, particularly mitochondria, derived from their 
ability to generate ROS and consequently, to activate pharyngeal expression of 
different proteins involved in oxidative stress pathways (Diomede et al., 2017). 
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4.3 Metal ions drive ROS generation and pharyngeal damage 
To elucidate the molecular mechanisms driving the ability of cardiotoxic LC to 
generate ROS, the role of metal ions has been investigated employing three 
monoclonal LC purified from urine (BJ) of AL patient with cardiac involvement 
and three negative control patients with multiple myeloma (MM) (Diomede et al., 
2017). 
To clarify the molecular mechanisms involved in ROS generation, experiments 
were carried out in cell-free conditions by using amplex red assay. As reported in 
Figure 10, cardiotoxic LC generate significantly higher levels of ROS, particularly 
H2O2, at variance with myeloma ones (725 ± 55.8 vs 278 ± 61.9 fluorescence 
intensity [FI] value for cardiotoxic LC and myeloma, respectively, p<0.01).  
The involvement of metal ions in this process has been then explored by eluting 
cardiotoxic LC and myeloma proteins on chelex, a metal-chelating resin 
(Diomede et al., 2017). 
To monitor conformational changes of the secondary structure caused by metal 
chelation, far-UV circular dichroism (CD) has been used. As shown in Figure 18, 
the presence of a metal ion chelating agent did not affect the secondary structure 
of cardiotoxic LC and myeloma proteins. They shared similar β- sheet content, 
consistent with the pattern of a typical immunoglobulin (Diomede et al., 2017). 
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Figure 18| Effect of metal ion chelators on the secondary structure of LC 
Far- UV CD spectra of cardiotoxic and myeloma LC treated or not with 5 mg/ml chelex. 
Proteins were used at 0.4 mg/ml in 50 mM sodium phosphate, pH 7.4, were incubated 
overnight at room temperature. Far-UV CD measurements were performed at 25°C in 50 
mM sodium phosphate, pH 7.4, with a Jasco J-700 spectropolarimeter (Jasco Europe, 
Cremella, Italy) using a quartz cuvette with a path length of 1 mm. Scans were conducted 
from 250 to 200 nm at a speed of 100 nm/min with a spectral bandwidth of 2 nm, a 
sensitivity of 20 degrees, and response time of 1 s. The α-helical and β-sheet content were 
calculated with K2D, CDSSTR, and CONTIN software applications CD. CD spectra 
represent the average of 10 scans. Data are shown as mean residue ellipticity (MRE, deg 
cm2 dmol-1) as a function of wavelength. All spectra presented a robust negative band at 
216–218 nm. Both cardiotoxic and myeloma proteins had a similar β-sheet content, 
consistent with the pattern of a typical immunoglobulin, which was not modified by the 
presence of a metal ion chelating agent. Adapted from (Diomede et al., 2017). 
 
Furthermore, the thermal stability of cardiotoxic LC and myeloma proteins after 
metal chelation was explored using guanidinium chloride (GdnHCl) as a 
denaturant. As shown in Figure 19, treatment with chelex resin did not affect the 
thermostability of proteins (Diomede et al., 2017). 
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Figure 19| Effect of metal ion chelators on the thermal stability of LC 
Melting data were recorded at 202 nm to monitor b-sheet unfolding on sample heating 
from 37°C to 80°C. Analyses were performed in a 1 mm path length quartz cuvette, 
temperature slope of 1°C/min, band width of 2 nm, data pitch of 0.2°C, and response time 
of 2 s. The thermal melt value (Tm) for each condition was calculated at the midpoint of 
the unfolding transition. No statistical difference among the various conditions tested was 
observed. No significant perturbations in thermostability were observed in LC after metal 
ion chelation. Adapted from (Diomede et al., 2017). 
 
Chelex treatment significantly attenuated the ability of cardiotoxic LC to produce 
hydrogen peroxide (725 ± 55.8 FI in cardiotoxic LC and 222 ± 101 FI in 
cardiotoxic LC + chelex) and entirely abolished ROS production caused by 
myeloma (278 ± 61.9 FI in myeloma and 4.17 ± 4.09 in myeloma + chelex) 
(Figure 20) (Diomede et al., 2017). 
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Figure 20| Effect of metal chelation on the ability of LC to generate ROS 
H2O2 produced by cardiotoxic LC and myeloma incubated 2 h with or without 5 mg/ml 
chelex. Mean ± SE of fluorescence intensity (FI), n=6, **p<0.01 vs cardiotoxic LC and 
°°p<0.01 vs myeloma, one-way ANOVA and Bonferroni’s post hoc test (Diomede et al., 
2017). 
 
However, the treatment with the chelex resin did not completely abolish the ROS 
production by cardiotoxic LC probably because some traces of metal ions might 
contain residue after the elution (Diomede et al., 2017). 
To evaluate the effect of metal chelation on C. elegans, cardiotoxic and myeloma 
proteins were incubated with chelex or ethylenediaminetetraacetic acid (EDTA) as 
metal- chelating compounds, and then diluted in metal-free water before 
administration to worms. In these experimental conditions, the pharyngeal 
impairment caused by cardiotoxic LC was wholly abolished by chelex or EDTA, 
whereas no changes were observed when worms were fed with myeloma proteins 
(Figure 21) (Diomede et al., 2017).  
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To understand the role of metal ions in driving the toxicity of cardiotoxic LC, 
proteins were first eluted on chelex resin and then incubated with different metal 
ions including copper (II), iron (II) and zinc (II). Amplex red assay revealed that 
the addition of copper and iron, but not zinc, to cardiotoxic and myeloma proteins 
restored their native ability to produce H2O2 (Figure 22) (Diomede et al., 2017).  
 
Figure 21| Metal-chelating compounds prevent the pharyngeal impairment caused by 
cardiotoxic LC  
Worms were fed for 2 h with 100 µg/ml cardiotoxic LC, myeloma proteins with or without 
5 mg/ml chelex or 10 µM EDTA. Control worms were incubated with 10 mM PBS, pH 7.4 
(Vehicle) only (dotted line). The mean ± 95% CI of pumps/min was calculated (horizontal 
line). Each dot is the mean of pumps/min for each protein (3 independent assays, n=30 
worms/assay). **p<0.01 vs Vehicle, °°p<0.01 vs cardiotoxic LC, one-way ANOVA, and 
Bonferroni's post hoc test (Diomede et al., 2017). 
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Figure 22| Effect of chelex on the ability of LC to generate ROS 
H2O2 produced by 45 µM cardiotoxic LC and myeloma treated with chelex and incubated 
2 h with 50 µM CuCl2, ZnCl2, or FeCl2. Control samples were incubated with chelex-
treated 10 mM PBS, pH 7.4. Mean ± SE of FI, n=12, **p<0.01 vs cardiotoxic LC 
incubated with chelex-treated PBS, pH 7.4, °°p<0.01 vs myeloma LC + chelex-treated 
PBS, pH 7.4, one- way ANOVA, and Bonferroni’s post hoc test (Diomede et al., 2017). 
 
However, only the addition of copper to cardiotoxic LC, but not to myeloma ones, 
caused a worsening of the pharyngeal dysfunction induced by cardiotoxic LC, 
whereas iron and zinc did not exert additional toxic effect (Figure 23) (Diomede 
et al., 2017). 
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Figure 23| Effect of metal ions on the ability of LC to affect pharyngeal pumping in 
worms 
Worms were fed for 2h with 100 µg/ml cardiotoxic LC, myeloma with or without 50 µM 
CuCl2, ZnCl2, or FeCl2. Control worms were incubated with 10 mM PBS, pH7.4 (Vehicle) 
only or 50 µM CuCl2, ZnCl2, and FeCl2. Pumping rate as mean pumps/min ± SE (n=20 
worms/assay, three assays). **p<0.01 vs vehicle, one-way ANOVA, and Bonferroni’s 
post hoc test. °°p<0.0001 vs cardiotoxic LC, two-way ANOVA, and Bonferroni’s post hoc 
test (Diomede et al., 2017). 
 
According to these findings, the addition of copper to chelex-treated cardiotoxic 
LC, but not zinc or iron, restores the toxicity of cardiotoxic LC and impairs the 
pharyngeal motility of C. elegans (Figure 24). In the same experimental 
conditions, it was observed that the pumping rate of C. elegans-fed myeloma 
protein was not affected by either copper or iron and zinc (Figure 23 and Figure 
24) (Diomede et al., 2017). 
All these findings indicate that, although iron and copper can drive the generation 
of H2O2 in cell-free conditions both in cardiotoxic and myeloma proteins, only 
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copper causes a pharyngeal dysfunction in vivo, when incubated with cardiotoxic 
LC (Diomede et al., 2017).  
 
Figure 24| Effect of chelex and copper on LC-induced toxicity 
Worms were fed for 2 h with 100 µg/ml cardiotoxic LC or myeloma treated or not with 5 
mg/ml of chelex and 50 µM copper. Control worms received 50 mM phosphate buffer, pH 
7.4, alone (Vehicle). Pumping rate as mean pumps/min ± SE (3 independent assays, n=30 
worms/assay). **p<0.01 vs Vehicle, °°p<0.01 vs cardiotoxic LC, one-way ANOVA, and 
Bonferroni’s post hoc test (Diomede et al., 2017). 
 
The ability of cardiotoxic LC to increase H2O2 production in the presence of 
copper indicates that the metal can be reduced from Cu2+ to Cu+ by the protein, 
suggesting that cardiotoxic LC possess reducing species to donate electrons, as the 
thiol group of cysteine. To prove this hypothesis, proteins were pre-incubated 
with iodoacetamide, an alkylating molecule able to bind the thiol group of 
cysteine, preventing copper binding and ROS generation. In this experimental 
condition, pre-incubation with iodoacetamide significantly prevents the H2O2 
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generation caused by the addition of copper to cardiotoxic LC solution (Figure 25) 
(Diomede et al., 2017).  
 
Figure 25| Iodoacetamide cleared the copper-induced increased production of H2O2 
H2O2 produced by cardiotoxic LC and myeloma previously treated for 3 h at 20°C with 
iodoacetamide and then incubated 2 h with 50 µM CuCl2. Mean ± SE of FI, n=9, 
**p<0.01 vs cardiotoxic LC not treated with iodoacetamide and °°p<0.01 vs cardiotoxic 
LC treated with iodoacetamide, one-way ANOVA, and Bonferroni's post hoc test. 
ANOVA, analysis of variance (Diomede et al., 2017). 
 
All these data demonstrate that metal ions, particularly copper, play a crucial role 
in driving ROS generation caused by cardiotoxic LC (Diomede et al., 2017). 
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4.4 Metal- binding compounds counteracted the cardiotoxic LC-
induced functional and structural damage on the worm’s pharynx 
To confirm the role of metal ions in driving oxidative stress in AL amyloidosis 
and to develop a pharmacological strategy aimed at restoring the metal 
homeostasis, 5-chloro-7-iodo-quinoline-8-ol (CQ) and PBT2 have been used 
(Diomede et al., 2017).  
As showed in Figure 26, both CQ and PBT2 counteracted the toxicity caused by 
cardiotoxic LC in a dose-dependent manner. In particular, PBT2 being 
significantly more effective than CQ, with an IC50 about 7000-fold lower (IC50= 
1.08 ± 1.1 nM and 7.5 ± 1.0 µM for PBT2 and CQ, respectively; p<0.01, 
Student’s t-test) (Diomede et al., 2017). 
 
Figure 26| Dose-response effect of metal ions chelating agents on LC-induced 
pharyngeal dysfunction 
Worms were fed 2 h 100 μg/ml cardiotoxic LC in the absence or presence of 0-25 μM CQ 
or 0-25 nM PBT2. Control worms received vehicle alone (dotted line). Mean ± SE, N=30. 
IC50 ± SD is reported (Diomede et al., 2017). 
 
Based on these data, CQ and PBT2 have been used at the optimal concentration of 
25 µM and 2 nM, respectively. At these concentrations, drugs alone did not alter 
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the pharyngeal motility of worms and prevented the pharyngeal dysfunction 
caused by cardiotoxic LC (Figure 27 A). To confirm that the protective effects 
exerted by CQ and PBT2 against cardiotoxic LC were not related to general 
antioxidant activity, additional experiments were carried out co-incubating both 
compounds with exogenous H2O2. Neither compounds counteracted H2O2-
induced pharyngeal toxicity, indicating that their protective effect is explicitly 
related to their ability to chelate metal ions (Figure 27 A). Moreover, both 
compounds counteracted H2O2 production, as revealed by amplex red assay 
(Figure 27 B) (Diomede et al., 2017).  
 
Figure 27| Effect of metal-binding compounds CQ and PBT2 on LC-induced 
pharyngeal dysfunction and H2O2 production 
(A) Effect of CQ and PBT2 on LC-induced pharyngeal dysfunction. Worms were fed for 2 
h with 100 µg/ml cardiotoxic LC in the absence or presence of 0–25 µM CQ or 0–25 nM 
PBT2. Control worms received vehicle alone (dotted line). Each value is the mean ± SE, 
n=30. IC50 ± SD is reported, p<0.01, Student’s t-test. (B) H2O2 produced by cardiotoxic 
LC incubated 2 h with or without 2 nM PBT2 or 25 µM CQ. Mean ± SE of FI, n=6, 
**p<0.01 vs cardiotoxic LC, one-way ANOVA and Bonferroni’s post hoc test. Adapted 
from (Diomede et al., 2017). 
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In all of these experimental conditions, the treatment with CQ and PBT2 did not 
affect the secondary structure and the thermal stability of the proteins (Figure 28) 
(Diomede et al., 2017). 
 
Figure 28| Effect of metal ion chelators on the secondary structure and thermal 
stability of LC 
(A) Far-UV CD spectra of cardiotoxic LC and myeloma proteins treated or not with 
5mg/ml chelex, 25 µM CQ, or 2 nM PBT2. All samples, at the protein concentration of 
0.4 mg/ml in 50 mM sodium phosphate, pH 7.4, were incubated overnight at room 
temperature. Far-UV CD measurements were performed at 25°C in 50 mM sodium 
phosphate, pH 7.4, with a Jasco J-700 spectropolarimeter using a quartz cuvette with a 
path length of 1 mm. Scans were conducted from 250 to 200nm at a speed of 100 nm/min 
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with a spectral bandwidth of 2 nm, a sensitivity of 20 mdegrees, and response time of 1 
sec. The α-helical and β-sheet content was calculated with K2D, CDSSTR, and CONTIN 
software applications CD. CD spectra represent the average of 10 scans. Data are shown 
as mean residue ellipticity (MRE, deg cm2 dmol-1) as the function of wavelength. All 
spectra presented a strong negative band at 216–218 nm. Both cardiotoxic and myeloma 
proteins had similar β-sheet content, consistent with the pattern of a typical 
immunoglobulin, which were not modified by the presence of metal ion chelating agent. 
(B) Melting data were recorded at 202 nm to monitor β-sheet unfolding on sample 
heating from 37°C to 80°C. Analyses were performed in a 1mmpath length quartz 
cuvette, temperature slope of 1°C/min, the bandwidth of 2 nm, data pitch of 0.2°C, and 
response time of 2 sec. The thermal melt value (Tm) for each condition was calculated at 
the midpoint of the unfolding transition. No statistical difference among the various 
conditions tested was observed. No significant perturbations in thermostability were 
observed in LC after metal ion chelation (Diomede et al., 2017).  
 
The protective effects exerted by CQ and PBT2 against cardiac LC-induced 
toxicity were also confirmed by mitosox red staining. As shown in Figure 29, both 
CQ and PBT2 protected nematodes from pharyngeal mitochondrial ROS 
generation caused by cardiotoxic LC but not against H2O2-induced toxicity 
(Figure 29) (Diomede et al., 2017). 
The protective effects of CQ and PBT2 on mitochondria of the pharynx of 
C.elegans have been then explored with TEM analysis. As shown in Figure 30, 
cardiotoxic LC at variance with myeloma, severely damage mitochondria in C. 
elegans’ pharynx. However, when cardiotoxic LC was administered in the 
presence of 2 nM PBT2 or 25 µM CQ a protective effect in pharyngeal cells has 
been observed (Figure 30 D-E). 
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Figure 29| Effect of CQ and PBT2 on LC-induced ROS generation 
Worms were fed for 2 h with 100 µg/ml cardiotoxic LC with or without 25 µM CQ or 2 
nM PBT2. H2O2 (1mM) was administered for 30 min with or without the drugs. Control 
worms received vehicle alone. Images obtained from the overlay of a contrast phase and 
MitoSOX fluorescence (arrows). Scale bar, 50 µm (Diomede et al., 2017).  
 
Similar protective effects have also been obtained when worms were fed with 
cardiotoxic LC in the presence of 50 µM TETRA, an antibiotic that has also 
antioxidant and metal ion chelator activity (Chin and Lach, 1975, Stoilova et al., 
2013), or 5 mM n-acetylcysteine (NAC), a prototypic antioxidant compound. 
Both compounds protect pharyngeal cells from mitochondria-induced damage 
(Figure 30 F-G) and counteract the pharyngeal dysfunction caused by cardiotoxic 
LC (Figure 31) (Diomede et al., 2017). 
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Figure 30| ROS-induced cardiotoxic LC severely disrupt C. elegans pharyngeal 
ultrastructure 
Representative images of worm’s pharynx obtained from the ultrastructural analysis by 
TEM in C. elegans fed for 2 h with (a) Vehicle, (b) myeloma protein, (c) cardiotoxic LC 
alone, or with (d) 25 µM CQ, (e) 2 nM PBT2, (f) 50 µM TETRA, or (g) 5 mM NAC. 
Images showed two pharyngeal muscles (pm) with their mitochondria (arrowheads) 
separated by a marginal cell (mc) and its mitochondria (arrows), placed at the corner of 
the pharyngeal channel (ch). Scale bar, 500 nm. Pharyngeal muscles of worms fed 
cardiotoxic LC resulted in damage to mitochondria, which exhibited a clustering pattern, 
irregular shape, swelling, and massive disruption of the internal components (i.e., 
cristae). Marginal cells, which contain many mitochondria due to their active role in 
contractile motor function, were severely compromised and myofilaments connected to 
the marginal cells, which were perfectly aligned in vehicle-fed worms, were deranged 
(Diomede et al., 2017). 
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Figure 31| Antioxidant compounds counteract the pharyngeal impairment caused by 
cardiotoxic LC 
Cardiotoxic LC and myeloma in 10 mM phosphate-buffered saline, pH 7.4 were 
administered to worms (100 worms/100 µl) at 100 µg/ml alone or with 50 µM TETRA or 
5 mM NAC. Control worms received vehicle alone (Vehicle). After incubation for 2 h in 
the absence of OP50 E. coli, worms were plated on NGM plates seeded with bacteria. 
Pharyngeal pumping was evaluated 20 h after plating and expressed as pumps/minute. 
**p<0.01 vs vehicle and °°p < 0.01 vs cardiotoxic LC, according to one-way ANOVA 
and Bonferroni's post hoc test. Adapted from (Diomede et al., 2017). 
 
 
To assess that the protective effects of CQ and PBT2 were not related to the 
specific purification procedure for BJ proteins, new experiments were carried out 
employing recombinant LC obtained from the same cardiac amyloid patients 
(Diomede et al., 2017). As reported in Table 5, both CQ and PBT2 similarly 
prevent from the pharyngeal dysfunction caused by the same cardiotoxic LC (H7), 
obtained from the urine of an AL-affected patient (BJ) or recombinantly (rec). 
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These data indicate that the damage mediated by metal ions was not an artefact of 
the protein purification procedure (Diomede et al., 2017).  
Table 5| Effect of CQ and PBT2 on the pharyngeal impairment caused by the natural 
Bence Jones and Recombinant LC from the Same Cardiac Amyloid Patient. 
 
Human monoclonal amyloidogenic cardiotoxic LC obtained as natural Bence Jones (H7-
BJ) and recombinant (H7-r) from the same cardiac amyloid patient were administered to 
worms (100 worms/100 µl) at 100 µg/ml in 10 mM PBS, pH 7.4, in the absence or 
presence of 25 µM CQ or 2 nM PBT2. Control worms received vehicle alone (Vehicle). 
After incubation for 2 h in the absence of OP50 E. coli, worms were plated on NGM 
plates seeded with bacteria. Pharyngeal functionality evaluated 20 h after plating. 
Pharyngeal pumping is expressed as pumps/minute ± SE. *p<0.01 vs vehicle, according 
to one-way analysis of variance followed by Bonferroni's post hoc test. Adapted from 
(Diomede et al., 2017).  
 
Overall, these findings indicate that cardiotoxic LC, though the disruption of 
metal ion homeostasis, generate ROS which directly damages the subcellular 
pharyngeal structures, notably mitochondria (Diomede et al., 2017).  
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4.5 Metal ions regulate the expression of genes involved in 
oxidative stress resistance 
To determine if CQ or PBT2 prevents the activation of the antioxidant defence 
system caused by ROS generation, transgenic TJ356, CL2070 and CF1553 strains 
have been used. To this end, cardiotoxic and myeloma proteins were administered 
to worm with or without 25 µM CQ or 2 nM PBT2, and the fluorescence 
intensities have been then measured. As reported in Figure 33, both CQ and PBT2 
counteracted the activation of DAF-16 induced by the cardiotoxic LC, preventing 
its nuclear translocation (Figure 32). A similar effect was observed after 
administration of 50 µM TETRA, but not 5 mM NAC (Figure 32) (Diomede et 
al., 2017). 
 
Figure 32| Metal ions drive the ability of cardiotoxic LC to promote DAF-16 
translocation from cytoplasm to nucleus in TJ356 transgenic worms 
The subcellular distribution of DAF-16 expression in worms fed 2 h: vehicle,100 µg/ml 
cardiotoxic LC with or without 25 µM CQ, 2 nM PBT2, 50 µM TETRA, or 5 mM NAC. 
According to DAF-16 localization, worms were divided into two phenotypes, including 
‘‘cytosolic’’ and ‘‘nuclear.’’ The percentage of DAF-16 localization concerning vehicle-
fed worms was calculated based on three experiments, n=100. Mean ± SE. **p<0.01 vs 
vehicle, °p<0.05 and °°p<0.01 vs cardiotoxic LC, one-way ANOVA, and Bonferroni’s 
post hoc test. Adapted from (Diomede et al., 2017).  
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According to this data, the co-incubation with CQ and PBT2 significantly reduced 
the HSP-16.2 and SOD-3 protein expression caused by cardiotoxic LC, reducing 
the GFP signal in the pharynx of CL2070 and CF1553 worms, respectively 
(Figure 33) (Diomede et al., 2017). 
 
Figure 33| Metal ions drive the ability of cardiotoxic LC to induce the pharyngeal 
expression of HSP-16.2 and SOD-3 
(A–D) Transgenic worms were fed for 2 h with (i) Vehicle (10mM PBS, pH 7.4), (ii) 100 
µg/ml myeloma, (iii)100 µg/ml cardiotoxic LC, (iv) cardiotoxic LC +25 µM CQ or (v) 
cardiotoxic LC + 2 nM PBT2. (A) Images of HSP-16.2 expression as overlays of GFP 
fluorescence and light microscopy in CL2070 transgenic worms. (C) Images of SOD-3 
expression as GFP fluorescence (arrows) in CF1553 transgenic worms. Scale bar, 50 
µm. Quantified GFP intensity in (B) CL2070 and (D) CF1553 worms in response to 
treatments. FI in each group was calculated as mean grey value ± SE based on three 
experiments, n=25. **p<0.01 vs Vehicle, °p<0.05 and °°p<0.01 vs cardiotoxic LC, one-
way ANOVA, and Bonferroni’s post hoc test (Diomede et al., 2017). 
 
The effect of CQ and PBT2 on survival was then evaluated.  It was already 
reported that cardiotoxic LC- fed worms show a significant reduction of lifespan 
compared to vehicle-fed worms (median survival: 13 and 9 days for vehicle- and 
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cardiotoxic LC-fed worms, respectively, p = 0.0001, Log-rank test) (Figure 34). 
The administration of a single dose of 25 µM CQ and 2 nM/day PBT2 prolonged 
the survival of cardiotoxic LC- treated worms, restoring their natural lifespan 
(median survival: 14 days for cardiotoxic LC + CQ-treated worms (p=0.036 vs 
cardiotoxic LC) and 13 days for cardiotoxic LC + 2 nM/day PBT2 (p=0.025 vs 
cardiotoxic LC) (Figure 34) (Diomede et al., 2017). 
 
Figure 34| Metal-binding compounds restore the natural nematode survival 
Kaplan–Meier survival curves treated with vehicle, 100 µg/ml of cardiotoxic LC or 
myeloma, in the absence or presence of 25 µM CQ or 2 nM PBT2. Survival is expressed 
as a percentage of the initial population (n=30 worms/group, three independent 
experiments) (Diomede et al., 2017).  
 
Overall, these results indicated that cardiotoxic LC through metal ion-mediated 
ROS production, activate consequent FOXO/DAF-16 pathway stimulating the 
genes involved in the control of the oxidative stress response and lifespan. The co-
incubation of cardiac LC with metal-binding compounds, such as CQ and PBT2, 
abolished the worm stress response and indicating that metal chelating compounds 
can be considered as innovative candidates for the treatment of AL patients with 
severe cardiac involvement (Diomede et al., 2017). 
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4.6 Synergic beneficial effect of PBT2 and TETRA 
In 2014, Diomede et al. demonstrated the protective effect of tetracyclines against 
toxicity exerts by cardiac LC in C. elegans (Diomede et al., 2014a). Based on 
these pre-clinical findings, Wechalekar et al. designed a clinical study to evaluate 
the cardioprotective effect of doxycycline in AL patients (Wechalekar and 
Whelan, 2017). Preliminary data indicated that orally administration of 100 mg of 
doxycycline (corresponding to about 100 µM/day) in addition to standard 
chemotherapy, cause a significant reduction of the early deaths in patients with 
cardiac AL (Wechalekar and Whelan, 2017). 
To develop a feasible clinical approach for AL amyloidosis, the combination of 
metal- binding compounds and tetracyclines have been evaluated in C. elegans. 
To reflect clinical conditions, worms were first incubated with cardiotoxic LC to 
induce damage of their pharynx. Then, drugs have been administered to worms 
for 30 min. The effects of 20 µM TETRA, a dose lower than that used in the 
clinic, 2 nM PBT2 and 25 µM CQ have been evaluated. As reported in Figure 
35A, in these experimental conditions TETRA was ineffective, whereas PBT2 but 
not CQ, restore the pharyngeal dysfunction caused by cardiotoxic LC (Diomede et 
al., 2017).  
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Figure 35| Co-administration of PBT2 and TETRA causes a synergic effect against 
pharyngeal dysfunction 
(A, B) Pharyngeal performance of worms fed 100 µg/ml cardiotoxic LC for 2 h and then 
treated for 30 min with (A) 25 µM CQ, 20 µM TETRA, or 2 nM PBT2 or with (B) 0.5–2 
nM PBT2 alone or together with 20 µM TETRA. Control worms fed vehicle alone. 
**p<0.001, *p<0.005 vs vehicle, °°p<0.001 vs cardiotoxic LC, one-way ANOVA, and 
Bonferroni’s post hoc test. §§p<0.01 significant interaction vs worms fed cardiotoxic LC 
+ 0.5 nM PBT2, two-way ANOVA, and Bonferroni’s post hoc test (Diomede et al., 2017).  
 
To determine the lowest effective dose of PBT2 able to improve the effect of 
TETRA, this metal-binding compound was administered at 2 or 0.5 nM 
concentrations. As reported in Figure 35 B, the single administration of PBT2 
alone at the lower concentration, it results ineffective. However, when it was used 
in combination with TETRA, they exert a synergistic and beneficial effect on the 
pharyngeal motility of worms (Figure 35 B). Moreover, when higher 
concentrations of PBT2 were used in combination with TETRA, no additional 
protective effects have been observed (Diomede et al., 2017).  
Although this combined treatment did not reverse the pharyngeal dysfunction to 
normal levels, these results indicate that the combined administration of low doses 
of PBT2 and TETRA may represent an innovative pharmacological approach to 
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break the vicious cycle of oxidative stress and heart damage induced by 
cardiotoxic LC (Diomede et al., 2017). 
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To date, the therapeutic approach used for AL amyloidosis, similarly to that 
employed for multiple myeloma, is aimed at the suppression of the plasma cell 
clone overproducing amyloidogenic LC (Merlini et al., 2011). This 
pharmacological treatment resulted in the reduction of the circulating LC although 
an effect on pre-formed amyloid deposits was not observed (D'Souza et al., 2017, 
Palladini et al., 2012). Eligible patients can also undergo autologous stem cell 
transplantation (D'Souza et al., 2017). It was estimated that about the 25% of the 
total AL- affected patients, due to their end-stage cardiac damage, is too fragile to 
receive chemotherapeutic treatment and transplantation (Milani et al., 2018).In the 
absence of any cure, the median survival of these patients is less than one year 
after diagnosis (Milani et al., 2018). This is why the accessibility to methods 
allowing the early diagnosis of AL as well as the development of innovative 
therapeutic approaches are needed to counteract the rapid progressing cardiac 
failure in patients suffering from AL amyloidosis, particularly in most 
compromised ones (Diomede et al., 2017).  
Actually no transgenic animals steadily overproducing LC and forming amyloid 
deposits are available. In the last years, various attempts have been made to 
develop AL transgenic mice, employing different pathogenic LC. However, no 
successful results have been reported because no fibrils formation has been 
observed (Buxbaum, 2009, Sirac et al., 2011). This might be due to the low 
concentrations of proteins synthesized and secreted in these animal models, at 
variance with human physiological conditions (Sirac et al., 2011). In 2000, Hrncic 
et al. developed a mouse model by injecting intraperitoneally of massive amounts 
of LC purified from AL-affected patients (Hrncic et al., 2000). Although it was 
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the only mouse model in which amyloid deposits have been detected, it was also 
reported that macrophages and neutrophils then surrounded these aggregates and 
then resorbed (Hrncic et al., 2000). This means that this model is not eligible for 
in vivo study on AL amyloidosis (Hrncic et al., 2000).  New in vivo approaches 
have been used to investigate the toxicity of the different protein assemblies 
(Diomede et al., 2014b). In 2013, Mishra et al. used zebrafish (Danio renio) 
embryos as an animal model to investigate the effects of LC purified from the 
urine of AL patients with cardiac injury (Mishra et al., 2013). In agreement to the 
clinical finding, the in vivo and ex vivo experiments, they demonstrated that 
through increased of oxidative stress, cardiotoxic LC cause cardiac damage, cell 
death and the reduction of overall survival of injected organisms, in the absence of 
fibrillary deposits (Mishra et al., 2013).  
Similar results were also obtained in 2014 by Diomede et al. employing the 
nematode C.elegans as a novel animal model to investigate the cardiotoxicity of 
LC (Diomede et al., 2014a). Although the main limitation of this model is the 
evolutionarily distance from vertebrates, in this worm many human stress 
pathways are conserved. This means that, although the translation to human 
pathology requires caution, this nematode is suitable to investigate the molecular 
mechanisms of different complex diseases (Diomede et al., 2014b, Diomede et al., 
2014a).  
Although the presence of amyloidogenic deposits is one of the main features of 
AL amyloidosis, soluble assemblies of LC, due to their ability to generate ROS, 
play a vital role in the onset and progression of the pathology (Diomede et al., 
2014a). Counteracting the toxic effects of ROS with antioxidants or tetracyclines, 
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resulted in a protective effect against the LC-induced damage both in vitro and in 
vivo (Diomede et al., 2014a, Liao et al., 2001). Based on these findings, 
doxycycline, has been used in a case-matched clinical study in which AL patients 
with severe cardiac involvement received doxycycline (100 mg, twice daily) in 
addition to the standard chemotherapy (Wechalekar and Whelan, 2017). As 
reported by Wechalekar et al., adjuvant doxycycline extended survival in AL-
affected patients with cardiac damage and NT-proBNP levels lower than 8500 
ng/L (stage IIIa) (Wechalekar and Whelan, 2017, Palladini et al., 2015). 
Unfortunately, this approach is ineffective in IIIb patients, with severe cardiac 
damage and NT-proBNP levels above 8500 ng/L (Wechalekar and Whelan, 2017, 
Palladini et al., 2015). 
In this study, I used the nematode C. elegans to investigate the molecular 
mechanisms involved in ROS generation, and in particular the role of metal ions 
in promoting the oxidative-mediated damage caused by cardiotoxic LC.  
The data obtained demonstrate that the ROS species generated by cardiac LC 
caused severe mitochondrial damage in the pharynx of worms (Diomede et al., 
2017). The translational relevance of this observation is supported by the TEM 
analysis performed on human cardiac biopsies from AL patients with severe 
cardiac involvement and admitted to heart transplantation. In these samples, the 
presence of a severe mitochondrial ultrastructural damage comparable to that 
observed in the pharynx of worms fed with cardiotoxic LC indicated that the 
impairment of mitochondria is actively involved in cardiac AL amyloidosis 
(Diomede et al., 2017).  
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The ability of cardiotoxic LC to co-localize with mitochondria was already 
described in vitro, in human primary cardiac fibroblasts and stem cell-derived 
cardiomyocytes (Lavatelli et al., 2015). Using a proteomic approach, it was also 
demonstrated that cardiotoxic LC, but not myeloma one, specifically interact with 
intracellular proteins involved in cell viability and metabolism, leading to severe 
alteration of mitochondrial morphology (Lavatelli et al., 2015). Overall, these 
findings indicate that LC affect the mitochondria of C. elegans’ pharynx and the 
vertebrate heart similarly. It should be noted that both these organs are rich in 
mitochondria due to their crucial role in providing the energy required for 
contraction (Diomede et al., 2017).  
Metal ions, particularly copper, play a crucial role in different neurodegenerative 
disorders due to their ability to interact and promote the aggregation of different 
amyloidogenic proteins, including Aβ protein and α-synuclein (Hunter et al., 
1997, Ostrerova-Golts et al., 2000). Studies conducted in vitro on recombinant LC 
reported that copper might promote their aggregation (Davis et al., 2001, Diomede 
et al., 2017). In this study it has been demonstrated that redox-active transition 
metal ions, particularly copper, specifically interact with cardiotoxic LC, driving 
their ability to generate ROS (Diomede et al., 2017).  
The ROS production is entirely unrelated to the germline gene of LC and to the 
purification’ method employed to obtain the proteins.  
The interaction of LC with metal ions is pivotal for the ROS-induced damage 
within the pharyngeal cells, particularly at the mitochondrial level (Diomede et 
al., 2017). In C. elegans, cells react to this insult by activating the transcription of 
different protective pathways. To gain insight into the molecular mechanism 
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driving cardiotoxic LC, the activation of the DAF-16/FOXO transcription factor, 
as a defence mechanism against the ROS-induced damage and devoted to re-
establish the cellular homeostasis, has been here demonstrated (Fonte et al., 2002, 
Heidler et al., 2010). It is known that in C. elegans, the phosphorylation and the 
nuclear translocation of DAF-16 trigger the transcription of genes involved in 
stress resistance and longevity, including sod-3 and hsp-16.2 (Fonte et al., 2002, 
Heidler et al., 2010). I demonstrated that cardiotoxic LC, but not myeloma, 
increase the expression of sod-3, mainly localized in the mitochondria of 
pharyngeal cells (Giglio et al., 1994, Hunter et al., 1997), and hsp-16.2 (Diomede 
et al., 2017).  
All these data have been collected and summarized in Figure 36. 
 
Figure 36| Proposed model for metal ion involvement in the mechanism underlying the 
LC-induced toxicity 
Redox-active transition metals, particularly copper, drive the ability of cardiotoxic LC to 
produce ROS in vivo. The excessive production of ROS can directly target the pharyngeal 
cells, damaging the organelle functions and the ultrastructure, particularly at the 
Discussion 
  110 
 
mitochondrial level. Mitochondria react to ROS by inducing the expression of the 
scavenger protein SOD-3. Also, the nuclear translocation of the FOXO/DAF-16 
transcription factor is activated, triggering a secondary ROS-induced cellular response 
by inducing the transcription of stress-responsive genes, including hsp- 16.2 and sod-3, 
and controlling longevity.  
 
To definitively block the ROS production, a new pharmacological strategy aimed 
not only at chelating metal ions but also to restore correct metal homeostasis, was 
here designed (Diomede et al., 2017). CQ and the new derivative PBT2 have been 
considered because both compounds specifically act as metal chelators and re-
establish metal homeostasis across the plasma membrane into cells (Crouch et al., 
2011). PBT2 has been recently developed for the treatment of Huntington disease 
and is currently under evaluation for the treatment of other neurodegenerative 
disorders characterized by cognitive impairment, neuronal degeneration and 
protein aggregation, including AD (Huntington Study Group Reach, 2015, Adlard 
et al., 2008).  
Both CQ and PBT2 protected C. elegans from the pharyngeal dysfunction, and the 
mitochondrial impairment caused by cardiotoxic LC blocking their ability to 
produce ROS.  PBT2 was active at a concentration 7000-fold lower than CQ 
(Diomede et al., 2017). Interestingly, neither compounds protected from the 
pharyngeal dysfunction nor mitochondrial damage caused by exogenous H2O2, 
demonstrating that their effect is not related to an antioxidant activity (Diomede et 
al., 2017). Also, these two drugs prevented the activation of the DAF-16/FOXO 
pathway and inhibited the transcription of sod-3 and has-16.2 genes (Diomede et 
al., 2017). The protective activity of PBT2 and CQ was not related to any 
antioxidant activity since they were not effective against the pharyngeal 
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dysfunction and mitochondrial damage caused by exogenous H2O2. The only 
antioxidant activity, as that exerted by NAC, was not sufficient to block the 
nuclear translocation of DAF-16 and the activation of SOD-3 and HSP-16.2 in 
cardiotoxic LC-fed worms, confirming that the regulation of metal ions 
homeostasis is crucial to abolish the worm stress response (Diomede et al., 2017). 
When PBT2 was co-administered with TETRA, a synergic protective effect was 
obtained. This allows reducing the doses of each drug to be employed 
significantly. These findings suggest that this approach can also be applied to 
improve the median survival of AL patients, particularly those of stage IIIb which 
have no benefits from the administration of doxycycline alone (Diomede et al., 
2017).  
Although this evidence are obtained in a simple multicellular organism, their 
relevance is supported by the evolutionary conservation of fundamental biological 
processes between C. elegans and humans and the similar subcellular alterations 
caused by cardiac LC in human heart and worms. This new conceptual advance 
paves the way for new pharmacological strategies aimed at totally inhibiting the 
vicious cycle of redox damage. 
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Overall, the results obtained in this thesis demonstrated that C. elegans could be 
used for rapid screening of LC in basic research and translational applications, to 
discriminate their cardiotoxic potential.  
I identify the mechanism by which cardiotoxic LC, but not myeloma proteins, are 
recognized as toxic by C. elegans. Moreover, using this nematode, I gain insight 
into the molecular mechanisms involved in AL amyloidosis identifying metal 
ions, already proposed to be involved in some central amyloidosis, as novel 
mediators of the LC toxicity (Gaeta and Hider, 2005, Wong and Duce, 2014). 
Based on these findings, I contributed to design and develop a new 
pharmacological strategy based on the use of metal chelating compound PBT2 in 
combination with tetracycline in addition to standard bortezomib-based 
chemotherapy. This approach, aimed at restoring the metal homeostasis and 
interrupting the vicious cycle of oxidative stress production caused by metal ions, 
can be used to improve cardiac response rate in newly diagnosed patients with AL 
amyloidosis, improving their life expectancy. 
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Appendix 1| Clinical and biochemical characteristics of patients at diagnosis of AL amyloidosis or multiple myeloma 
 
Reference ranges: serum λ FLC <26.3 mg/l, κ/λ ratio 0.26–1.65; serum creatinine <1.18 mg/dl in men, <1.02 mg/dl in women; NT-
proBNP (Perfetti et al., 1996) <332 ng/l; BNP, <50 ng/l; cTnI <0.04 ng/ml. 
aAccording to Gertz et al. (Gertz et al., 2005). 
bAccording to the International Consensus Panel criteria (Gertz et al., 2005). 
cEntirely constituted by BJ proteins. 
dBNP (ng/l). 
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Appendix 2| Effect of hydrogen peroxide on DAF-16 nuclear translocation and HSP-
16.2 and SOD-3 pharyngeal expression. 
 
Transgenic worms were fed with 1 mM H2O2 for 30 min. Worms were then plated on 
NGM agar plates seeded with E. coli. (A) Representative image of DAF-16/GFP 
distribution in transgenic TJ356 C. elegans. Scale bar = 50 nm. (B) HSP-16.2 and SOD-3 
expression, as visualized by GFP fluorescence, in transgenic CL2070 and CF1553 
worms, respectively. Scale bar =50 µm. 
